| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Platelet Aggregation Inhibitors | 441 | 2024 | 3201 | 32.690 |
Why?
|
| Myocardial Infarction | 449 | 2024 | 11891 | 19.980 |
Why?
|
| Acute Coronary Syndrome | 175 | 2024 | 2362 | 16.990 |
Why?
|
| Ticlopidine | 158 | 2018 | 895 | 16.710 |
Why?
|
| Coronary Artery Disease | 280 | 2024 | 6661 | 15.410 |
Why?
|
| Aspirin | 225 | 2024 | 3365 | 14.720 |
Why?
|
| Cardiovascular Diseases | 331 | 2024 | 15740 | 12.480 |
Why?
|
| Angioplasty, Balloon, Coronary | 144 | 2020 | 1880 | 12.450 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 91 | 2024 | 379 | 12.220 |
Why?
|
| Adenosine Monophosphate | 55 | 2024 | 283 | 11.550 |
Why?
|
| Drug-Eluting Stents | 75 | 2024 | 758 | 11.330 |
Why?
|
| Diabetes Mellitus, Type 2 | 193 | 2024 | 12281 | 9.560 |
Why?
|
| Eicosapentaenoic Acid | 53 | 2024 | 613 | 8.900 |
Why?
|
| Stents | 148 | 2023 | 3303 | 8.600 |
Why?
|
| Stroke | 266 | 2024 | 9945 | 8.570 |
Why?
|
| Coronary Artery Bypass | 81 | 2024 | 2273 | 8.520 |
Why?
|
| Heart Failure | 200 | 2024 | 11835 | 8.360 |
Why?
|
| Registries | 285 | 2024 | 8449 | 7.760 |
Why?
|
| Thrombosis | 121 | 2024 | 3052 | 7.680 |
Why?
|
| Hypertriglyceridemia | 23 | 2024 | 316 | 7.680 |
Why?
|
| Hemorrhage | 199 | 2024 | 3604 | 7.650 |
Why?
|
| Fibrinolytic Agents | 95 | 2024 | 2167 | 7.420 |
Why?
|
| Aortic Valve Stenosis | 47 | 2024 | 2064 | 6.710 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 97 | 2024 | 3333 | 6.690 |
Why?
|
| Coronary Thrombosis | 46 | 2020 | 486 | 6.670 |
Why?
|
| Anticoagulants | 118 | 2024 | 4896 | 6.530 |
Why?
|
| Atherosclerosis | 107 | 2024 | 3524 | 6.400 |
Why?
|
| Hypertension | 93 | 2023 | 8595 | 6.280 |
Why?
|
| Humans | 2018 | 2024 | 760261 | 6.160 |
Why?
|
| Atrial Fibrillation | 102 | 2024 | 5201 | 6.120 |
Why?
|
| Hospital Mortality | 143 | 2024 | 5420 | 5.840 |
Why?
|
| Treatment Outcome | 610 | 2024 | 64947 | 5.800 |
Why?
|
| Cardiology | 50 | 2024 | 1723 | 5.640 |
Why?
|
| Randomized Controlled Trials as Topic | 188 | 2024 | 10340 | 5.580 |
Why?
|
| Drug Therapy, Combination | 201 | 2024 | 6499 | 5.500 |
Why?
|
| Brain Ischemia | 79 | 2023 | 3127 | 5.370 |
Why?
|
| Peripheral Arterial Disease | 58 | 2024 | 1305 | 5.300 |
Why?
|
| Renal Artery | 18 | 2022 | 368 | 5.260 |
Why?
|
| Coronary Angiography | 93 | 2024 | 4560 | 5.250 |
Why?
|
| Risk Factors | 550 | 2024 | 74269 | 5.060 |
Why?
|
| Angina, Unstable | 39 | 2023 | 926 | 4.950 |
Why?
|
| Hypoglycemic Agents | 77 | 2024 | 3149 | 4.950 |
Why?
|
| Secondary Prevention | 72 | 2024 | 1548 | 4.940 |
Why?
|
| Myocardial Ischemia | 52 | 2024 | 2161 | 4.790 |
Why?
|
| Renal Insufficiency, Chronic | 48 | 2024 | 2296 | 4.780 |
Why?
|
| Myocardial Revascularization | 49 | 2024 | 841 | 4.770 |
Why?
|
| Adamantane | 23 | 2021 | 169 | 4.560 |
Why?
|
| Risk Assessment | 242 | 2024 | 24086 | 4.520 |
Why?
|
| Patient Readmission | 60 | 2024 | 3327 | 4.480 |
Why?
|
| Sympathectomy | 20 | 2023 | 90 | 4.450 |
Why?
|
| Aged | 869 | 2024 | 168995 | 4.410 |
Why?
|
| Aortic Valve | 38 | 2023 | 1996 | 4.390 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 60 | 2018 | 638 | 4.330 |
Why?
|
| Dipeptides | 23 | 2021 | 410 | 4.250 |
Why?
|
| Blood Pressure | 73 | 2022 | 8523 | 4.130 |
Why?
|
| Guideline Adherence | 68 | 2021 | 2283 | 4.110 |
Why?
|
| Antihypertensive Agents | 44 | 2023 | 2063 | 4.060 |
Why?
|
| Male | 1053 | 2024 | 359413 | 4.000 |
Why?
|
| Coronary Vessels | 36 | 2023 | 3112 | 3.950 |
Why?
|
| Coronary Stenosis | 24 | 2024 | 820 | 3.900 |
Why?
|
| Adenosine | 28 | 2023 | 833 | 3.880 |
Why?
|
| Heart Valve Prosthesis Implantation | 31 | 2023 | 1583 | 3.840 |
Why?
|
| Proton Pump Inhibitors | 22 | 2022 | 551 | 3.790 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 22 | 2021 | 334 | 3.780 |
Why?
|
| Coronary Vessel Anomalies | 7 | 2022 | 316 | 3.760 |
Why?
|
| Coronary Disease | 70 | 2021 | 5993 | 3.700 |
Why?
|
| Female | 1028 | 2024 | 391011 | 3.660 |
Why?
|
| Shock, Cardiogenic | 24 | 2024 | 734 | 3.660 |
Why?
|
| Saphenous Vein | 19 | 2022 | 538 | 3.580 |
Why?
|
| Middle Aged | 788 | 2024 | 220175 | 3.580 |
Why?
|
| Thrombolytic Therapy | 49 | 2024 | 2108 | 3.560 |
Why?
|
| Coronary Restenosis | 29 | 2021 | 426 | 3.490 |
Why?
|
| Time Factors | 270 | 2024 | 40133 | 3.480 |
Why?
|
| Glycosides | 10 | 2024 | 112 | 3.420 |
Why?
|
| Glucosides | 35 | 2024 | 536 | 3.400 |
Why?
|
| Hospitalization | 122 | 2024 | 10761 | 3.380 |
Why?
|
| Double-Blind Method | 160 | 2024 | 12412 | 3.320 |
Why?
|
| Cholesterol, LDL | 43 | 2024 | 2422 | 3.230 |
Why?
|
| United States | 346 | 2024 | 72363 | 3.210 |
Why?
|
| Warfarin | 36 | 2021 | 1516 | 3.100 |
Why?
|
| Graft Occlusion, Vascular | 22 | 2022 | 560 | 3.100 |
Why?
|
| Blood Platelets | 42 | 2023 | 2522 | 3.070 |
Why?
|
| Clinical Trials as Topic | 62 | 2024 | 8058 | 3.060 |
Why?
|
| Cardiovascular Agents | 27 | 2022 | 864 | 3.060 |
Why?
|
| Benzhydryl Compounds | 41 | 2024 | 942 | 3.030 |
Why?
|
| Tissue Plasminogen Activator | 35 | 2022 | 1190 | 3.010 |
Why?
|
| Platelet Aggregation | 26 | 2023 | 805 | 3.000 |
Why?
|
| Practice Guidelines as Topic | 95 | 2024 | 7468 | 2.950 |
Why?
|
| American Heart Association | 42 | 2022 | 1081 | 2.930 |
Why?
|
| Peripheral Vascular Diseases | 27 | 2018 | 515 | 2.930 |
Why?
|
| Diabetes Mellitus | 59 | 2024 | 5884 | 2.920 |
Why?
|
| Thrombectomy | 18 | 2023 | 707 | 2.860 |
Why?
|
| Vascular Diseases | 21 | 2023 | 1180 | 2.850 |
Why?
|
| Fatty Acids, Omega-3 | 14 | 2024 | 1387 | 2.850 |
Why?
|
| Denervation | 12 | 2022 | 277 | 2.840 |
Why?
|
| Heart Valve Prosthesis | 27 | 2023 | 1494 | 2.790 |
Why?
|
| Kidney | 44 | 2024 | 7072 | 2.750 |
Why?
|
| Heart Diseases | 20 | 2023 | 2809 | 2.710 |
Why?
|
| Ischemic Attack, Transient | 24 | 2023 | 899 | 2.710 |
Why?
|
| Gastrointestinal Hemorrhage | 21 | 2024 | 1130 | 2.650 |
Why?
|
| Dyslipidemias | 23 | 2024 | 895 | 2.630 |
Why?
|
| Ischemia | 29 | 2024 | 1893 | 2.610 |
Why?
|
| Antithrombins | 17 | 2020 | 313 | 2.590 |
Why?
|
| Aged, 80 and over | 296 | 2024 | 58947 | 2.490 |
Why?
|
| Quality Indicators, Health Care | 25 | 2020 | 1822 | 2.490 |
Why?
|
| Anticholesteremic Agents | 23 | 2024 | 988 | 2.370 |
Why?
|
| Fractional Flow Reserve, Myocardial | 9 | 2023 | 329 | 2.330 |
Why?
|
| Diabetes Complications | 23 | 2022 | 1342 | 2.330 |
Why?
|
| Troponin | 15 | 2023 | 516 | 2.290 |
Why?
|
| Chest Pain | 16 | 2022 | 1106 | 2.290 |
Why?
|
| Thromboembolism | 20 | 2023 | 1016 | 2.260 |
Why?
|
| Hypertension, Renal | 6 | 2023 | 141 | 2.260 |
Why?
|
| Foramen Ovale, Patent | 6 | 2019 | 214 | 2.250 |
Why?
|
| Quality of Health Care | 42 | 2020 | 4361 | 2.240 |
Why?
|
| Mitral Valve Insufficiency | 13 | 2023 | 1419 | 2.230 |
Why?
|
| Endovascular Procedures | 26 | 2023 | 2135 | 2.200 |
Why?
|
| Cardiovascular System | 14 | 2024 | 850 | 2.190 |
Why?
|
| Follow-Up Studies | 198 | 2024 | 39254 | 2.160 |
Why?
|
| Carotid Stenosis | 25 | 2024 | 872 | 2.140 |
Why?
|
| Catheter Ablation | 17 | 2023 | 2755 | 2.130 |
Why?
|
| Cerebrovascular Disorders | 25 | 2023 | 1500 | 2.090 |
Why?
|
| Inpatients | 26 | 2024 | 2578 | 2.030 |
Why?
|
| Bariatric Surgery | 19 | 2022 | 1006 | 2.010 |
Why?
|
| Postoperative Complications | 61 | 2024 | 15680 | 2.010 |
Why?
|
| Lipid Regulating Agents | 7 | 2024 | 28 | 2.010 |
Why?
|
| Cholesterol | 21 | 2024 | 2925 | 2.000 |
Why?
|
| Primary Prevention | 22 | 2023 | 1207 | 1.970 |
Why?
|
| Platelet Function Tests | 26 | 2019 | 303 | 1.920 |
Why?
|
| Incidence | 122 | 2024 | 21378 | 1.910 |
Why?
|
| Radial Artery | 11 | 2022 | 196 | 1.890 |
Why?
|
| Lipoprotein(a) | 17 | 2024 | 499 | 1.860 |
Why?
|
| Hospital Costs | 16 | 2021 | 976 | 1.860 |
Why?
|
| Angina Pectoris, Variant | 3 | 2020 | 56 | 1.840 |
Why?
|
| Healthcare Disparities | 25 | 2022 | 3381 | 1.830 |
Why?
|
| Patient Discharge | 41 | 2023 | 3475 | 1.830 |
Why?
|
| Triglycerides | 24 | 2024 | 2476 | 1.820 |
Why?
|
| Stroke Volume | 54 | 2024 | 5513 | 1.820 |
Why?
|
| Exercise Test | 11 | 2024 | 2125 | 1.790 |
Why?
|
| Diabetic Nephropathies | 15 | 2024 | 988 | 1.780 |
Why?
|
| United States Food and Drug Administration | 12 | 2022 | 1675 | 1.740 |
Why?
|
| Heart Valve Diseases | 12 | 2023 | 1047 | 1.740 |
Why?
|
| Coronary Occlusion | 6 | 2021 | 308 | 1.720 |
Why?
|
| Risk Reduction Behavior | 16 | 2020 | 1109 | 1.720 |
Why?
|
| Electrocardiography | 41 | 2023 | 6413 | 1.720 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 11 | 2021 | 253 | 1.720 |
Why?
|
| Hypercholesterolemia | 17 | 2020 | 1155 | 1.690 |
Why?
|
| Survival Rate | 83 | 2024 | 12806 | 1.660 |
Why?
|
| Hospitals | 36 | 2022 | 3929 | 1.650 |
Why?
|
| Drug Administration Schedule | 56 | 2024 | 4900 | 1.650 |
Why?
|
| Sirolimus | 13 | 2018 | 1548 | 1.630 |
Why?
|
| Diabetic Angiopathies | 17 | 2019 | 822 | 1.620 |
Why?
|
| Atrial Appendage | 8 | 2024 | 292 | 1.620 |
Why?
|
| Thiophenes | 14 | 2015 | 587 | 1.620 |
Why?
|
| Drug Resistance | 21 | 2018 | 1617 | 1.620 |
Why?
|
| Databases, Factual | 48 | 2021 | 8018 | 1.600 |
Why?
|
| Plaque, Atherosclerotic | 12 | 2024 | 1520 | 1.590 |
Why?
|
| Omeprazole | 7 | 2016 | 112 | 1.580 |
Why?
|
| Obesity | 43 | 2024 | 12915 | 1.570 |
Why?
|
| Immunoglobulin Fab Fragments | 21 | 2017 | 465 | 1.560 |
Why?
|
| Mitral Valve | 13 | 2023 | 1486 | 1.550 |
Why?
|
| Blood Vessel Prosthesis Implantation | 20 | 2023 | 1426 | 1.540 |
Why?
|
| Angina Pectoris | 11 | 2022 | 969 | 1.540 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 19 | 2023 | 1521 | 1.530 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 8 | 2023 | 347 | 1.510 |
Why?
|
| Retrospective Studies | 200 | 2024 | 80301 | 1.480 |
Why?
|
| Diastole | 7 | 2020 | 788 | 1.470 |
Why?
|
| Influenza, Human | 11 | 2024 | 1532 | 1.440 |
Why?
|
| Sodium-Glucose Transporter 2 | 9 | 2023 | 98 | 1.430 |
Why?
|
| Health Behavior | 12 | 2016 | 2621 | 1.420 |
Why?
|
| Platelet Activation | 13 | 2017 | 661 | 1.410 |
Why?
|
| Hypolipidemic Agents | 15 | 2024 | 626 | 1.400 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 9 | 2013 | 253 | 1.370 |
Why?
|
| Recurrence | 58 | 2024 | 8487 | 1.370 |
Why?
|
| Medication Adherence | 15 | 2023 | 2163 | 1.370 |
Why?
|
| Research Design | 29 | 2022 | 6181 | 1.360 |
Why?
|
| Metals | 10 | 2019 | 736 | 1.350 |
Why?
|
| Myocardial Reperfusion | 10 | 2017 | 347 | 1.350 |
Why?
|
| Dose-Response Relationship, Drug | 65 | 2021 | 10829 | 1.340 |
Why?
|
| Quality Improvement | 29 | 2022 | 3840 | 1.340 |
Why?
|
| Intracranial Hemorrhages | 24 | 2023 | 844 | 1.330 |
Why?
|
| Odds Ratio | 72 | 2022 | 9712 | 1.330 |
Why?
|
| Anti-Arrhythmia Agents | 8 | 2023 | 784 | 1.320 |
Why?
|
| Health Status | 16 | 2024 | 4081 | 1.310 |
Why?
|
| Albuminuria | 8 | 2024 | 659 | 1.300 |
Why?
|
| Sodium-Glucose Transporter 1 | 4 | 2021 | 112 | 1.300 |
Why?
|
| Incretins | 5 | 2021 | 103 | 1.290 |
Why?
|
| Adrenergic beta-Antagonists | 18 | 2022 | 1256 | 1.280 |
Why?
|
| Renal Dialysis | 15 | 2024 | 1802 | 1.280 |
Why?
|
| Fibromuscular Dysplasia | 2 | 2019 | 56 | 1.260 |
Why?
|
| Systole | 10 | 2020 | 947 | 1.260 |
Why?
|
| Aortic Aneurysm, Abdominal | 9 | 2020 | 1199 | 1.260 |
Why?
|
| Masks | 2 | 2021 | 209 | 1.230 |
Why?
|
| Patient Selection | 34 | 2022 | 4276 | 1.220 |
Why?
|
| Administration, Oral | 43 | 2023 | 4044 | 1.220 |
Why?
|
| Proportional Hazards Models | 88 | 2024 | 12532 | 1.210 |
Why?
|
| Bioprosthesis | 9 | 2020 | 599 | 1.210 |
Why?
|
| Atherectomy, Coronary | 4 | 2024 | 146 | 1.210 |
Why?
|
| Cause of Death | 43 | 2024 | 3723 | 1.200 |
Why?
|
| Prosthesis Design | 29 | 2023 | 2127 | 1.200 |
Why?
|
| Placebos | 7 | 2020 | 1672 | 1.200 |
Why?
|
| Carotid Arteries | 11 | 2021 | 951 | 1.190 |
Why?
|
| Femoral Artery | 11 | 2021 | 831 | 1.190 |
Why?
|
| Prevalence | 65 | 2024 | 15687 | 1.180 |
Why?
|
| Sex Factors | 45 | 2024 | 10530 | 1.160 |
Why?
|
| Prognosis | 92 | 2024 | 29636 | 1.150 |
Why?
|
| Chi-Square Distribution | 39 | 2018 | 3466 | 1.150 |
Why?
|
| Survival Analysis | 64 | 2021 | 10185 | 1.140 |
Why?
|
| Coronary Circulation | 13 | 2023 | 1578 | 1.140 |
Why?
|
| Angiotensin Receptor Antagonists | 13 | 2023 | 1025 | 1.140 |
Why?
|
| Cardiac Surgical Procedures | 14 | 2024 | 3618 | 1.130 |
Why?
|
| Palliative Care | 5 | 2022 | 3607 | 1.130 |
Why?
|
| Pandemics | 15 | 2022 | 8621 | 1.130 |
Why?
|
| Multivariate Analysis | 72 | 2020 | 12156 | 1.120 |
Why?
|
| Troponin T | 13 | 2023 | 774 | 1.120 |
Why?
|
| Pacemaker, Artificial | 7 | 2023 | 815 | 1.110 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 13 | 2019 | 2282 | 1.110 |
Why?
|
| Disease Management | 15 | 2021 | 2508 | 1.100 |
Why?
|
| Heparin | 18 | 2020 | 1655 | 1.100 |
Why?
|
| Comorbidity | 56 | 2024 | 10552 | 1.090 |
Why?
|
| Cardiopulmonary Resuscitation | 9 | 2023 | 1004 | 1.080 |
Why?
|
| Kaplan-Meier Estimate | 50 | 2024 | 6545 | 1.080 |
Why?
|
| Coronavirus Infections | 9 | 2020 | 3086 | 1.080 |
Why?
|
| Endarterectomy, Carotid | 14 | 2018 | 560 | 1.070 |
Why?
|
| Pneumonia, Viral | 9 | 2020 | 3206 | 1.070 |
Why?
|
| Glucagon-Like Peptides | 6 | 2024 | 159 | 1.060 |
Why?
|
| Defibrillators, Implantable | 12 | 2019 | 1499 | 1.060 |
Why?
|
| Perioperative Care | 9 | 2024 | 1032 | 1.060 |
Why?
|
| Logistic Models | 59 | 2023 | 13311 | 1.050 |
Why?
|
| Ventricular Function, Left | 19 | 2024 | 3870 | 1.040 |
Why?
|
| Age Factors | 60 | 2021 | 18415 | 1.040 |
Why?
|
| Kidney Failure, Chronic | 13 | 2022 | 2469 | 1.040 |
Why?
|
| Prospective Studies | 152 | 2024 | 54263 | 1.040 |
Why?
|
| Patient Admission | 12 | 2019 | 1384 | 1.030 |
Why?
|
| Incidental Findings | 2 | 2021 | 698 | 1.020 |
Why?
|
| Atrial Flutter | 6 | 2023 | 258 | 1.020 |
Why?
|
| Absorbable Implants | 7 | 2019 | 345 | 1.010 |
Why?
|
| Arteritis | 3 | 2019 | 162 | 1.000 |
Why?
|
| Paclitaxel | 8 | 2012 | 1738 | 1.000 |
Why?
|
| Receptors, Purinergic P2Y12 | 9 | 2019 | 124 | 1.000 |
Why?
|
| Infusions, Intravenous | 22 | 2024 | 2235 | 0.990 |
Why?
|
| Diabetic Cardiomyopathies | 7 | 2019 | 96 | 0.990 |
Why?
|
| Heart | 8 | 2024 | 4392 | 0.990 |
Why?
|
| Blood Glucose | 24 | 2022 | 6375 | 0.990 |
Why?
|
| C-Reactive Protein | 26 | 2024 | 3822 | 0.980 |
Why?
|
| Mineral Oil | 3 | 2023 | 25 | 0.980 |
Why?
|
| Blood Loss, Surgical | 3 | 2019 | 657 | 0.980 |
Why?
|
| Thrombophilia | 2 | 2019 | 307 | 0.960 |
Why?
|
| Echocardiography, Transesophageal | 8 | 2024 | 1108 | 0.960 |
Why?
|
| Glomerular Filtration Rate | 24 | 2024 | 2178 | 0.960 |
Why?
|
| Coronary Vasospasm | 2 | 2016 | 83 | 0.950 |
Why?
|
| Predictive Value of Tests | 58 | 2023 | 15273 | 0.950 |
Why?
|
| Pulmonary Valve | 2 | 2018 | 414 | 0.950 |
Why?
|
| Adult | 176 | 2024 | 219847 | 0.940 |
Why?
|
| Diabetic Ketoacidosis | 4 | 2022 | 257 | 0.920 |
Why?
|
| Renal Insufficiency | 9 | 2024 | 820 | 0.920 |
Why?
|
| Medicare | 41 | 2023 | 6771 | 0.920 |
Why?
|
| Hirudins | 14 | 2020 | 194 | 0.920 |
Why?
|
| Research Report | 3 | 2021 | 370 | 0.920 |
Why?
|
| Piperazines | 11 | 2015 | 2520 | 0.910 |
Why?
|
| Drug Substitution | 8 | 2021 | 296 | 0.900 |
Why?
|
| Angioplasty, Balloon | 9 | 2020 | 597 | 0.900 |
Why?
|
| Hyperlipidemias | 9 | 2024 | 782 | 0.890 |
Why?
|
| Nephritis | 2 | 2023 | 149 | 0.890 |
Why?
|
| Length of Stay | 35 | 2021 | 6472 | 0.890 |
Why?
|
| Evidence-Based Medicine | 25 | 2020 | 3696 | 0.880 |
Why?
|
| Embolic Protection Devices | 3 | 2021 | 43 | 0.880 |
Why?
|
| Propensity Score | 23 | 2021 | 1918 | 0.880 |
Why?
|
| Cohort Studies | 92 | 2024 | 41317 | 0.870 |
Why?
|
| Postoperative Care | 7 | 2020 | 1478 | 0.870 |
Why?
|
| Aortic Valve Insufficiency | 4 | 2023 | 584 | 0.870 |
Why?
|
| Tachycardia, Ventricular | 5 | 2023 | 1302 | 0.860 |
Why?
|
| Prosthesis Failure | 8 | 2022 | 1206 | 0.860 |
Why?
|
| Arteriosclerosis | 9 | 2013 | 1064 | 0.860 |
Why?
|
| Leg | 3 | 2016 | 1091 | 0.850 |
Why?
|
| Lithotripsy | 1 | 2024 | 142 | 0.850 |
Why?
|
| Antibodies, Monoclonal | 26 | 2023 | 9196 | 0.850 |
Why?
|
| Anemia | 7 | 2021 | 1511 | 0.840 |
Why?
|
| Severity of Illness Index | 51 | 2024 | 15827 | 0.840 |
Why?
|
| Drug Approval | 4 | 2021 | 816 | 0.840 |
Why?
|
| Rheumatic Heart Disease | 2 | 2023 | 167 | 0.840 |
Why?
|
| Imines | 6 | 2012 | 34 | 0.830 |
Why?
|
| Peptide Fragments | 22 | 2024 | 5120 | 0.830 |
Why?
|
| Gastrectomy | 9 | 2022 | 677 | 0.820 |
Why?
|
| Carotid Artery Diseases | 10 | 2018 | 881 | 0.820 |
Why?
|
| Phospholipids | 4 | 2022 | 789 | 0.820 |
Why?
|
| Nutrition Surveys | 9 | 2022 | 1727 | 0.820 |
Why?
|
| Ventricular Outflow Obstruction | 3 | 2021 | 265 | 0.820 |
Why?
|
| Cardiology Service, Hospital | 3 | 2019 | 242 | 0.810 |
Why?
|
| Gastric Inhibitory Polypeptide | 1 | 2022 | 66 | 0.810 |
Why?
|
| Tissue and Organ Harvesting | 5 | 2022 | 377 | 0.810 |
Why?
|
| Tobacco Use Disorder | 2 | 2021 | 700 | 0.800 |
Why?
|
| Postoperative Hemorrhage | 9 | 2020 | 422 | 0.800 |
Why?
|
| Clinical Trials, Phase III as Topic | 10 | 2022 | 859 | 0.800 |
Why?
|
| Risk | 30 | 2019 | 9629 | 0.800 |
Why?
|
| Acute Disease | 42 | 2024 | 7268 | 0.790 |
Why?
|
| Cost-Benefit Analysis | 21 | 2024 | 5507 | 0.780 |
Why?
|
| Gastric Bypass | 11 | 2021 | 826 | 0.780 |
Why?
|
| Cardiac Imaging Techniques | 2 | 2022 | 269 | 0.780 |
Why?
|
| Ventricular Dysfunction, Left | 8 | 2022 | 2129 | 0.780 |
Why?
|
| Influenza Vaccines | 7 | 2024 | 770 | 0.770 |
Why?
|
| Erythrocyte Transfusion | 3 | 2019 | 566 | 0.770 |
Why?
|
| Eligibility Determination | 3 | 2021 | 419 | 0.740 |
Why?
|
| Acute Kidney Injury | 14 | 2022 | 1935 | 0.730 |
Why?
|
| Hypertrophy, Left Ventricular | 5 | 2020 | 853 | 0.730 |
Why?
|
| Poverty | 5 | 2022 | 2695 | 0.720 |
Why?
|
| Pyridones | 8 | 2018 | 788 | 0.720 |
Why?
|
| Mitral Valve Annuloplasty | 2 | 2019 | 146 | 0.710 |
Why?
|
| Attitude to Health | 3 | 2021 | 2028 | 0.710 |
Why?
|
| Smoking | 25 | 2024 | 9070 | 0.710 |
Why?
|
| Artificial Intelligence | 6 | 2023 | 2557 | 0.710 |
Why?
|
| Body Mass Index | 34 | 2024 | 12901 | 0.700 |
Why?
|
| Vitamin E | 2 | 2015 | 872 | 0.700 |
Why?
|
| Weight Loss | 14 | 2022 | 2683 | 0.700 |
Why?
|
| Periodontitis | 2 | 2022 | 560 | 0.700 |
Why?
|
| Electric Countershock | 3 | 2018 | 537 | 0.690 |
Why?
|
| Creatine Kinase, MB Form | 9 | 2013 | 211 | 0.690 |
Why?
|
| Venous Thromboembolism | 9 | 2024 | 1866 | 0.690 |
Why?
|
| Hospitals, Teaching | 7 | 2018 | 1166 | 0.680 |
Why?
|
| Cardiotoxins | 1 | 2019 | 37 | 0.680 |
Why?
|
| Health Resources | 4 | 2020 | 936 | 0.680 |
Why?
|
| Recovery of Function | 14 | 2021 | 2982 | 0.680 |
Why?
|
| Congresses as Topic | 5 | 2018 | 804 | 0.680 |
Why?
|
| Aortic Aneurysm, Thoracic | 2 | 2017 | 693 | 0.670 |
Why?
|
| 2-Pyridinylmethylsulfinylbenzimidazoles | 3 | 2014 | 35 | 0.670 |
Why?
|
| Translating | 1 | 2020 | 148 | 0.660 |
Why?
|
| Inflammation | 24 | 2024 | 10757 | 0.660 |
Why?
|
| Angioplasty | 6 | 2020 | 360 | 0.660 |
Why?
|
| Gastrointestinal Diseases | 5 | 2024 | 1189 | 0.660 |
Why?
|
| Embolism | 7 | 2020 | 408 | 0.660 |
Why?
|
| Intracranial Thrombosis | 1 | 2020 | 109 | 0.650 |
Why?
|
| Diffusion of Innovation | 2 | 2021 | 730 | 0.650 |
Why?
|
| Pyridines | 15 | 2018 | 2877 | 0.650 |
Why?
|
| Multicenter Studies as Topic | 15 | 2022 | 1723 | 0.650 |
Why?
|
| Coagulants | 1 | 2019 | 46 | 0.650 |
Why?
|
| Social Class | 6 | 2020 | 2005 | 0.650 |
Why?
|
| Career Choice | 2 | 2015 | 755 | 0.640 |
Why?
|
| Heart Rate | 12 | 2023 | 4169 | 0.640 |
Why?
|
| Anti-Inflammatory Agents | 4 | 2021 | 1799 | 0.640 |
Why?
|
| Asymptomatic Diseases | 2 | 2021 | 582 | 0.630 |
Why?
|
| Receptors, Purinergic P2Y1 | 2 | 2016 | 42 | 0.630 |
Why?
|
| Cholesterol, HDL | 6 | 2023 | 1817 | 0.630 |
Why?
|
| Periodontal Diseases | 1 | 2022 | 452 | 0.630 |
Why?
|
| Sleep | 7 | 2021 | 4746 | 0.630 |
Why?
|
| Anti-Obesity Agents | 2 | 2021 | 229 | 0.630 |
Why?
|
| Catheterization, Peripheral | 5 | 2021 | 342 | 0.620 |
Why?
|
| Patient Care Team | 7 | 2024 | 2510 | 0.620 |
Why?
|
| Awareness | 2 | 2020 | 644 | 0.620 |
Why?
|
| Athletes | 2 | 2016 | 1125 | 0.620 |
Why?
|
| Pyrazoles | 11 | 2018 | 1992 | 0.610 |
Why?
|
| Breast Implants | 1 | 2022 | 411 | 0.610 |
Why?
|
| Myocardium | 6 | 2020 | 4688 | 0.610 |
Why?
|
| Diagnostic Imaging | 3 | 2021 | 3526 | 0.610 |
Why?
|
| Heart Transplantation | 4 | 2023 | 3217 | 0.610 |
Why?
|
| Education, Medical, Continuing | 2 | 2020 | 830 | 0.600 |
Why?
|
| Hemodynamics | 11 | 2020 | 4169 | 0.600 |
Why?
|
| Mortality | 24 | 2023 | 2916 | 0.590 |
Why?
|
| Smoking Cessation | 9 | 2020 | 2064 | 0.590 |
Why?
|
| Autonomic Denervation | 2 | 2016 | 6 | 0.590 |
Why?
|
| Receptor, PAR-1 | 5 | 2012 | 114 | 0.590 |
Why?
|
| Viremia | 1 | 2020 | 708 | 0.580 |
Why?
|
| Renin-Angiotensin System | 5 | 2023 | 739 | 0.580 |
Why?
|
| Calculi | 1 | 2017 | 49 | 0.580 |
Why?
|
| Drug Interactions | 13 | 2017 | 1426 | 0.580 |
Why?
|
| Coronary Aneurysm | 2 | 2018 | 233 | 0.580 |
Why?
|
| Apolipoprotein A-I | 3 | 2024 | 297 | 0.570 |
Why?
|
| Coated Materials, Biocompatible | 5 | 2020 | 317 | 0.570 |
Why?
|
| Arteriovenous Shunt, Surgical | 2 | 2022 | 294 | 0.570 |
Why?
|
| Arthritis, Rheumatoid | 8 | 2024 | 3763 | 0.570 |
Why?
|
| Potassium | 1 | 2021 | 1318 | 0.570 |
Why?
|
| Mandatory Reporting | 1 | 2018 | 124 | 0.570 |
Why?
|
| Cerebral Hemorrhage | 13 | 2023 | 2660 | 0.570 |
Why?
|
| Diuretics | 3 | 2022 | 612 | 0.570 |
Why?
|
| Drug Labeling | 2 | 2019 | 251 | 0.570 |
Why?
|
| Metoprolol | 2 | 2015 | 92 | 0.560 |
Why?
|
| Ventricular Remodeling | 4 | 2022 | 1259 | 0.560 |
Why?
|
| Kidney Diseases | 10 | 2023 | 2093 | 0.560 |
Why?
|
| Uvula | 1 | 2016 | 16 | 0.560 |
Why?
|
| Toothpastes | 1 | 2016 | 13 | 0.560 |
Why?
|
| Cardiotonic Agents | 6 | 2019 | 546 | 0.560 |
Why?
|
| Pulmonary Valve Insufficiency | 1 | 2018 | 143 | 0.560 |
Why?
|
| Diagnostic Errors | 2 | 2022 | 1266 | 0.550 |
Why?
|
| Reimbursement, Incentive | 2 | 2019 | 543 | 0.550 |
Why?
|
| Antirheumatic Agents | 6 | 2024 | 1374 | 0.550 |
Why?
|
| Societies, Medical | 14 | 2021 | 3903 | 0.550 |
Why?
|
| Embolization, Therapeutic | 5 | 2014 | 1411 | 0.550 |
Why?
|
| Sodium Dodecyl Sulfate | 1 | 2016 | 127 | 0.540 |
Why?
|
| Anthracyclines | 1 | 2018 | 283 | 0.540 |
Why?
|
| Defibrillators | 1 | 2016 | 40 | 0.540 |
Why?
|
| Stomatitis, Aphthous | 1 | 2016 | 52 | 0.530 |
Why?
|
| Immunosuppressive Agents | 6 | 2020 | 4168 | 0.530 |
Why?
|
| Death, Sudden, Cardiac | 12 | 2021 | 1572 | 0.530 |
Why?
|
| Seasons | 3 | 2022 | 1523 | 0.530 |
Why?
|
| Dinucleoside Phosphates | 1 | 2016 | 73 | 0.520 |
Why?
|
| Piperidines | 11 | 2024 | 1650 | 0.520 |
Why?
|
| Quality Assurance, Health Care | 9 | 2017 | 2178 | 0.520 |
Why?
|
| Drug Tolerance | 2 | 2017 | 369 | 0.520 |
Why?
|
| Decision Making | 6 | 2022 | 3924 | 0.520 |
Why?
|
| Vascular Surgical Procedures | 4 | 2020 | 1469 | 0.520 |
Why?
|
| Antioxidants | 3 | 2018 | 1668 | 0.520 |
Why?
|
| Europe | 20 | 2024 | 3433 | 0.520 |
Why?
|
| Consensus | 12 | 2020 | 3106 | 0.520 |
Why?
|
| Forecasting | 10 | 2022 | 2931 | 0.520 |
Why?
|
| Blood Coagulation | 8 | 2024 | 1156 | 0.510 |
Why?
|
| Mitral Valve Stenosis | 3 | 2023 | 348 | 0.510 |
Why?
|
| Obesity, Morbid | 10 | 2021 | 1287 | 0.510 |
Why?
|
| Docosahexaenoic Acids | 7 | 2024 | 912 | 0.510 |
Why?
|
| Blood Pressure Determination | 6 | 2020 | 641 | 0.510 |
Why?
|
| Myocardial Bridging | 1 | 2015 | 11 | 0.500 |
Why?
|
| Venous Thrombosis | 7 | 2024 | 1293 | 0.500 |
Why?
|
| Intention to Treat Analysis | 8 | 2021 | 422 | 0.500 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2020 | 709 | 0.500 |
Why?
|
| Outpatients | 15 | 2018 | 1606 | 0.500 |
Why?
|
| Peptides | 9 | 2016 | 4358 | 0.500 |
Why?
|
| Information Dissemination | 3 | 2018 | 1132 | 0.500 |
Why?
|
| School Health Services | 2 | 2016 | 382 | 0.500 |
Why?
|
| Blood Flow Velocity | 4 | 2018 | 1375 | 0.500 |
Why?
|
| Rural Population | 4 | 2020 | 2267 | 0.500 |
Why?
|
| Electronic Health Records | 13 | 2021 | 4763 | 0.490 |
Why?
|
| Gastroparesis | 1 | 2017 | 137 | 0.490 |
Why?
|
| Dyspepsia | 2 | 2016 | 118 | 0.490 |
Why?
|
| Age Distribution | 9 | 2019 | 2893 | 0.490 |
Why?
|
| Gagging | 1 | 2014 | 5 | 0.490 |
Why?
|
| Ultrasonography, Interventional | 12 | 2023 | 1503 | 0.490 |
Why?
|
| Assisted Circulation | 1 | 2015 | 102 | 0.490 |
Why?
|
| Patient Acceptance of Health Care | 5 | 2022 | 3159 | 0.490 |
Why?
|
| Referral and Consultation | 6 | 2018 | 3598 | 0.480 |
Why?
|
| Neoplasms | 18 | 2024 | 22066 | 0.480 |
Why?
|
| Leukocyte Count | 7 | 2006 | 1600 | 0.480 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 558 | 0.480 |
Why?
|
| Forearm | 2 | 2016 | 429 | 0.480 |
Why?
|
| Stockings, Compression | 1 | 2014 | 37 | 0.480 |
Why?
|
| Tablets, Enteric-Coated | 2 | 2022 | 22 | 0.480 |
Why?
|
| Heart Injuries | 3 | 2021 | 208 | 0.480 |
Why?
|
| Natriuretic Peptide, Brain | 12 | 2024 | 1705 | 0.480 |
Why?
|
| Communicable Disease Control | 1 | 2021 | 844 | 0.480 |
Why?
|
| Periodicals as Topic | 6 | 2021 | 1470 | 0.480 |
Why?
|
| Calcium Channel Agonists | 1 | 2014 | 27 | 0.480 |
Why?
|
| Potassium Deficiency | 1 | 2014 | 10 | 0.470 |
Why?
|
| Lipoproteins | 1 | 2019 | 882 | 0.470 |
Why?
|
| Health Knowledge, Attitudes, Practice | 9 | 2021 | 3967 | 0.470 |
Why?
|
| Patient Education as Topic | 7 | 2021 | 2311 | 0.470 |
Why?
|
| Renal Artery Obstruction | 5 | 2014 | 224 | 0.470 |
Why?
|
| Counterpulsation | 2 | 2015 | 18 | 0.470 |
Why?
|
| Heart Conduction System | 4 | 2016 | 1016 | 0.470 |
Why?
|
| Heart Murmurs | 1 | 2014 | 94 | 0.470 |
Why?
|
| Drug Utilization | 6 | 2019 | 1195 | 0.470 |
Why?
|
| Pericarditis | 2 | 2022 | 135 | 0.460 |
Why?
|
| Health Status Disparities | 5 | 2021 | 1819 | 0.460 |
Why?
|
| United States Department of Veterans Affairs | 9 | 2020 | 917 | 0.460 |
Why?
|
| Internal Mammary-Coronary Artery Anastomosis | 1 | 2014 | 39 | 0.460 |
Why?
|
| Combined Modality Therapy | 22 | 2020 | 8551 | 0.460 |
Why?
|
| Drug Prescriptions | 4 | 2018 | 1673 | 0.460 |
Why?
|
| Therapies, Investigational | 1 | 2015 | 111 | 0.460 |
Why?
|
| Sex Distribution | 10 | 2019 | 2295 | 0.460 |
Why?
|
| Potassium, Dietary | 1 | 2014 | 104 | 0.450 |
Why?
|
| Autonomic Nerve Block | 1 | 2014 | 81 | 0.450 |
Why?
|
| Intra-Aortic Balloon Pumping | 4 | 2018 | 227 | 0.450 |
Why?
|
| Schools, Medical | 1 | 2020 | 878 | 0.450 |
Why?
|
| Drug Delivery Systems | 6 | 2007 | 2218 | 0.450 |
Why?
|
| Canada | 16 | 2024 | 2128 | 0.450 |
Why?
|
| Ventricular Premature Complexes | 1 | 2014 | 113 | 0.450 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2015 | 619 | 0.440 |
Why?
|
| Drug Monitoring | 4 | 2021 | 966 | 0.440 |
Why?
|
| Medical Records | 2 | 2018 | 1407 | 0.440 |
Why?
|
| Diabetic Neuropathies | 1 | 2017 | 406 | 0.440 |
Why?
|
| Thrombocytopenia | 3 | 2018 | 1174 | 0.430 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 4 | 2017 | 152 | 0.430 |
Why?
|
| Recombinant Proteins | 16 | 2020 | 6543 | 0.430 |
Why?
|
| Medicaid | 8 | 2021 | 2811 | 0.430 |
Why?
|
| Injections, Intravenous | 7 | 2017 | 1388 | 0.430 |
Why?
|
| Ambulatory Care | 10 | 2020 | 2783 | 0.430 |
Why?
|
| Fasting | 5 | 2020 | 1603 | 0.430 |
Why?
|
| Biomedical Technology | 1 | 2015 | 211 | 0.430 |
Why?
|
| Thiazolidinediones | 4 | 2015 | 465 | 0.430 |
Why?
|
| Lipids | 7 | 2023 | 3336 | 0.430 |
Why?
|
| Sex Characteristics | 8 | 2024 | 2627 | 0.430 |
Why?
|
| Vitamin K | 3 | 2023 | 321 | 0.430 |
Why?
|
| Infection Control | 1 | 2020 | 983 | 0.430 |
Why?
|
| Veterans | 5 | 2023 | 2640 | 0.430 |
Why?
|
| Echocardiography | 14 | 2022 | 4980 | 0.430 |
Why?
|
| Endothelium, Vascular | 5 | 2017 | 4437 | 0.420 |
Why?
|
| Device Removal | 2 | 2017 | 634 | 0.420 |
Why?
|
| Patient Protection and Affordable Care Act | 3 | 2021 | 1200 | 0.420 |
Why?
|
| Accreditation | 4 | 2021 | 477 | 0.420 |
Why?
|
| Chromium Alloys | 1 | 2012 | 72 | 0.420 |
Why?
|
| Enalapril | 2 | 2017 | 313 | 0.420 |
Why?
|
| HIV | 1 | 2020 | 1579 | 0.420 |
Why?
|
| Life Style | 7 | 2017 | 3888 | 0.420 |
Why?
|
| Serine Proteinase Inhibitors | 4 | 2024 | 179 | 0.420 |
Why?
|
| Students | 2 | 2020 | 1722 | 0.420 |
Why?
|
| Single-Blind Method | 7 | 2022 | 1577 | 0.420 |
Why?
|
| Tropanes | 3 | 2021 | 51 | 0.420 |
Why?
|
| Endpoint Determination | 6 | 2021 | 597 | 0.410 |
Why?
|
| Vulnerable Populations | 1 | 2018 | 696 | 0.410 |
Why?
|
| Popliteal Artery | 3 | 2018 | 312 | 0.410 |
Why?
|
| Drugs, Investigational | 2 | 2016 | 214 | 0.410 |
Why?
|
| Health Policy | 4 | 2021 | 2678 | 0.410 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 4 | 2015 | 435 | 0.410 |
Why?
|
| Models, Cardiovascular | 6 | 2015 | 974 | 0.400 |
Why?
|
| Delivery of Health Care | 6 | 2020 | 5324 | 0.400 |
Why?
|
| Adenosine Diphosphate | 6 | 2013 | 429 | 0.400 |
Why?
|
| Drug Design | 2 | 2015 | 1062 | 0.400 |
Why?
|
| Hypoglycemia | 7 | 2019 | 888 | 0.400 |
Why?
|
| Abdominal Fat | 1 | 2014 | 223 | 0.400 |
Why?
|
| Cyclooxygenase Inhibitors | 3 | 2019 | 364 | 0.390 |
Why?
|
| Residence Characteristics | 5 | 2018 | 2058 | 0.390 |
Why?
|
| Vaccination | 5 | 2022 | 3360 | 0.390 |
Why?
|
| Critical Care | 5 | 2020 | 2699 | 0.390 |
Why?
|
| Algorithms | 15 | 2022 | 13967 | 0.390 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2014 | 274 | 0.390 |
Why?
|
| Enoxaparin | 5 | 2023 | 397 | 0.390 |
Why?
|
| Independent Living | 2 | 2013 | 568 | 0.390 |
Why?
|
| Heart-Assist Devices | 6 | 2021 | 1290 | 0.390 |
Why?
|
| Biomedical Research | 6 | 2020 | 3421 | 0.390 |
Why?
|
| Endocarditis, Bacterial | 3 | 2022 | 445 | 0.390 |
Why?
|
| Cross-Sectional Studies | 25 | 2023 | 25928 | 0.390 |
Why?
|
| Mammaplasty | 1 | 2022 | 1239 | 0.390 |
Why?
|
| Population Surveillance | 3 | 2018 | 2609 | 0.390 |
Why?
|
| Syncope | 1 | 2014 | 428 | 0.390 |
Why?
|
| Muscarinic Antagonists | 3 | 2021 | 138 | 0.390 |
Why?
|
| Schools | 1 | 2020 | 1474 | 0.380 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2015 | 701 | 0.380 |
Why?
|
| Health Services Accessibility | 9 | 2022 | 5396 | 0.380 |
Why?
|
| Diagnosis, Differential | 10 | 2022 | 12968 | 0.380 |
Why?
|
| Psoriasis | 1 | 2019 | 939 | 0.380 |
Why?
|
| Syndrome | 18 | 2010 | 3278 | 0.380 |
Why?
|
| Thrombin | 2 | 2005 | 593 | 0.380 |
Why?
|
| Vasopressins | 1 | 2012 | 355 | 0.380 |
Why?
|
| Catheterization, Swan-Ganz | 1 | 2011 | 87 | 0.380 |
Why?
|
| Blood Vessel Prosthesis | 3 | 2021 | 945 | 0.370 |
Why?
|
| Treatment Failure | 8 | 2024 | 2646 | 0.370 |
Why?
|
| Breast Neoplasms | 4 | 2022 | 21065 | 0.370 |
Why?
|
| Creatinine | 10 | 2022 | 1906 | 0.370 |
Why?
|
| Polymorphism, Genetic | 6 | 2016 | 4286 | 0.370 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2017 | 819 | 0.370 |
Why?
|
| Medicine | 1 | 2019 | 943 | 0.370 |
Why?
|
| Physicians | 7 | 2021 | 4590 | 0.370 |
Why?
|
| Family Characteristics | 2 | 2013 | 1001 | 0.370 |
Why?
|
| Health Education | 2 | 2016 | 1049 | 0.370 |
Why?
|
| Arrhythmias, Cardiac | 4 | 2021 | 2255 | 0.370 |
Why?
|
| Counseling | 5 | 2020 | 1550 | 0.370 |
Why?
|
| Young Adult | 41 | 2023 | 58673 | 0.360 |
Why?
|
| Emergency Medical Services | 8 | 2020 | 1927 | 0.360 |
Why?
|
| Benzazepines | 1 | 2012 | 311 | 0.360 |
Why?
|
| Nitric Oxide | 4 | 2024 | 2141 | 0.360 |
Why?
|
| Tetrazoles | 5 | 2022 | 901 | 0.360 |
Why?
|
| Aneurysm, False | 2 | 2023 | 257 | 0.360 |
Why?
|
| Dyspnea | 6 | 2023 | 1352 | 0.360 |
Why?
|
| Linear Models | 15 | 2017 | 5876 | 0.360 |
Why?
|
| Tomography, Optical Coherence | 6 | 2020 | 2878 | 0.360 |
Why?
|
| Cough | 1 | 2014 | 595 | 0.360 |
Why?
|
| Metformin | 5 | 2020 | 912 | 0.360 |
Why?
|
| Heart Arrest | 5 | 2022 | 1506 | 0.360 |
Why?
|
| Edema | 1 | 2014 | 772 | 0.350 |
Why?
|
| Withholding Treatment | 4 | 2021 | 613 | 0.350 |
Why?
|
| Immunologic Factors | 1 | 2019 | 1589 | 0.350 |
Why?
|
| Spironolactone | 1 | 2014 | 411 | 0.350 |
Why?
|
| Laboratories | 2 | 2022 | 461 | 0.350 |
Why?
|
| Fellowships and Scholarships | 2 | 2017 | 1118 | 0.350 |
Why?
|
| Erectile Dysfunction | 1 | 2014 | 452 | 0.350 |
Why?
|
| Education, Medical, Graduate | 4 | 2017 | 2359 | 0.350 |
Why?
|
| Cardiopulmonary Bypass | 2 | 2020 | 1096 | 0.340 |
Why?
|
| Circadian Rhythm | 4 | 2017 | 2567 | 0.340 |
Why?
|
| Disease Progression | 24 | 2024 | 13505 | 0.340 |
Why?
|
| Clinical Competence | 8 | 2018 | 4786 | 0.340 |
Why?
|
| Office Visits | 1 | 2014 | 597 | 0.340 |
Why?
|
| Aftercare | 6 | 2023 | 918 | 0.340 |
Why?
|
| Guidelines as Topic | 6 | 2017 | 1395 | 0.340 |
Why?
|
| Antineoplastic Agents | 2 | 2023 | 13629 | 0.340 |
Why?
|
| Cardiomyopathies | 5 | 2021 | 1945 | 0.340 |
Why?
|
| Pyrimidines | 6 | 2024 | 3011 | 0.340 |
Why?
|
| Lipoproteins, HDL | 3 | 2024 | 667 | 0.330 |
Why?
|
| Lower Extremity | 6 | 2018 | 1196 | 0.330 |
Why?
|
| Muscle Strength | 1 | 2014 | 619 | 0.330 |
Why?
|
| Arterial Occlusive Diseases | 5 | 2022 | 752 | 0.330 |
Why?
|
| RNA | 1 | 2019 | 2721 | 0.330 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2013 | 549 | 0.330 |
Why?
|
| Education, Medical | 2 | 2020 | 1728 | 0.330 |
Why?
|
| Angiography | 6 | 2022 | 1605 | 0.330 |
Why?
|
| France | 7 | 2023 | 511 | 0.330 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 7 | 2021 | 3223 | 0.330 |
Why?
|
| Antibodies, Neutralizing | 1 | 2019 | 1933 | 0.330 |
Why?
|
| Morbidity | 10 | 2024 | 1765 | 0.330 |
Why?
|
| Anti-Ulcer Agents | 1 | 2010 | 113 | 0.330 |
Why?
|
| Confidence Intervals | 9 | 2013 | 2932 | 0.330 |
Why?
|
| Early Ambulation | 2 | 2006 | 49 | 0.320 |
Why?
|
| Insulin Resistance | 10 | 2022 | 3960 | 0.320 |
Why?
|
| Troponin I | 4 | 2024 | 634 | 0.320 |
Why?
|
| Colchicine | 4 | 2024 | 261 | 0.320 |
Why?
|
| Triazoles | 1 | 2014 | 904 | 0.320 |
Why?
|
| Oxygen Inhalation Therapy | 3 | 2017 | 404 | 0.320 |
Why?
|
| Interdisciplinary Communication | 3 | 2024 | 934 | 0.310 |
Why?
|
| Vegetables | 1 | 2014 | 1198 | 0.310 |
Why?
|
| Biological Availability | 5 | 2024 | 395 | 0.310 |
Why?
|
| Arachidonic Acid | 3 | 2022 | 434 | 0.310 |
Why?
|
| Pyrazines | 1 | 2014 | 1200 | 0.310 |
Why?
|
| Diabetes Mellitus, Type 1 | 5 | 2023 | 3451 | 0.310 |
Why?
|
| Endoscopy | 4 | 2021 | 1841 | 0.310 |
Why?
|
| Sleep Apnea, Obstructive | 7 | 2017 | 1859 | 0.310 |
Why?
|
| Thoracic Surgery | 3 | 2024 | 722 | 0.310 |
Why?
|
| Retreatment | 4 | 2018 | 600 | 0.310 |
Why?
|
| Regional Medical Programs | 1 | 2008 | 68 | 0.310 |
Why?
|
| Hematinics | 1 | 2011 | 281 | 0.310 |
Why?
|
| Sodium Bicarbonate | 2 | 2018 | 62 | 0.300 |
Why?
|
| Preventive Medicine | 2 | 2020 | 250 | 0.300 |
Why?
|
| North America | 9 | 2020 | 1282 | 0.300 |
Why?
|
| Hospital Charges | 2 | 2021 | 359 | 0.300 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 2 | 2022 | 129 | 0.300 |
Why?
|
| Vascular Patency | 6 | 2022 | 901 | 0.300 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 3 | 2020 | 400 | 0.290 |
Why?
|
| Minority Groups | 3 | 2021 | 1199 | 0.290 |
Why?
|
| Autoimmune Diseases | 2 | 2018 | 2250 | 0.290 |
Why?
|
| Insurance Coverage | 5 | 2022 | 1939 | 0.290 |
Why?
|
| Hydrocortisone | 1 | 2015 | 1798 | 0.290 |
Why?
|
| Iliac Artery | 2 | 2013 | 344 | 0.290 |
Why?
|
| Insurance Benefits | 3 | 2020 | 191 | 0.290 |
Why?
|
| Health Personnel | 2 | 2020 | 3310 | 0.290 |
Why?
|
| Pulmonary Embolism | 3 | 2024 | 2544 | 0.290 |
Why?
|
| Biphenyl Compounds | 3 | 2022 | 988 | 0.290 |
Why?
|
| Brain Infarction | 2 | 2020 | 292 | 0.290 |
Why?
|
| Bayes Theorem | 6 | 2023 | 2325 | 0.290 |
Why?
|
| PPAR gamma | 2 | 2007 | 484 | 0.290 |
Why?
|
| Fibroblast Growth Factors | 2 | 2023 | 867 | 0.290 |
Why?
|
| Fee-for-Service Plans | 4 | 2020 | 705 | 0.290 |
Why?
|
| Economics, Hospital | 2 | 2020 | 212 | 0.290 |
Why?
|
| Endocarditis | 2 | 2022 | 351 | 0.290 |
Why?
|
| Mass Screening | 3 | 2021 | 5422 | 0.290 |
Why?
|
| Glucose | 9 | 2023 | 4361 | 0.290 |
Why?
|
| Catheters | 4 | 2022 | 425 | 0.280 |
Why?
|
| Sweden | 5 | 2023 | 1381 | 0.280 |
Why?
|
| Thienopyridines | 3 | 2010 | 12 | 0.280 |
Why?
|
| Dietary Supplements | 1 | 2020 | 3389 | 0.280 |
Why?
|
| Purinergic P2 Receptor Antagonists | 5 | 2012 | 72 | 0.280 |
Why?
|
| Acetylcysteine | 2 | 2018 | 264 | 0.280 |
Why?
|
| Intracranial Embolism | 3 | 2021 | 192 | 0.280 |
Why?
|
| Prediabetic State | 2 | 2022 | 550 | 0.280 |
Why?
|
| Interleukin-6 | 5 | 2024 | 3207 | 0.270 |
Why?
|
| Australia | 13 | 2020 | 1288 | 0.270 |
Why?
|
| Health Care Costs | 7 | 2023 | 3257 | 0.270 |
Why?
|
| Erythropoietin | 1 | 2011 | 720 | 0.270 |
Why?
|
| Prosthesis Implantation | 3 | 2020 | 593 | 0.270 |
Why?
|
| Cross-Over Studies | 9 | 2022 | 2061 | 0.270 |
Why?
|
| Aortic Rupture | 2 | 2020 | 313 | 0.270 |
Why?
|
| Health Promotion | 2 | 2015 | 2208 | 0.270 |
Why?
|
| Hospitalists | 1 | 2010 | 295 | 0.270 |
Why?
|
| Unnecessary Procedures | 2 | 2020 | 413 | 0.270 |
Why?
|
| Tricuspid Valve Insufficiency | 2 | 2023 | 355 | 0.270 |
Why?
|
| Walking | 1 | 2013 | 1190 | 0.270 |
Why?
|
| Pharmacogenetics | 4 | 2018 | 680 | 0.270 |
Why?
|
| Punctures | 4 | 2020 | 367 | 0.270 |
Why?
|
| Hemostasis, Surgical | 2 | 2008 | 129 | 0.270 |
Why?
|
| Blood Transfusion | 6 | 2020 | 1328 | 0.260 |
Why?
|
| Carbonic Anhydrase II | 1 | 2005 | 22 | 0.260 |
Why?
|
| Protons | 2 | 2015 | 1113 | 0.260 |
Why?
|
| Vasodilator Agents | 4 | 2020 | 977 | 0.260 |
Why?
|
| Sodium Chloride | 2 | 2018 | 596 | 0.260 |
Why?
|
| Costs and Cost Analysis | 4 | 2021 | 1679 | 0.260 |
Why?
|
| Ontario | 7 | 2020 | 405 | 0.260 |
Why?
|
| Thromboxane B2 | 4 | 2022 | 147 | 0.260 |
Why?
|
| Terminology as Topic | 2 | 2024 | 1534 | 0.260 |
Why?
|
| Electrocardiography, Ambulatory | 2 | 2021 | 578 | 0.260 |
Why?
|
| Migraine Disorders | 1 | 2018 | 1693 | 0.250 |
Why?
|
| Insurance, Health | 7 | 2021 | 2500 | 0.250 |
Why?
|
| Streptokinase | 1 | 2005 | 187 | 0.250 |
Why?
|
| Helicobacter pylori | 1 | 2008 | 377 | 0.250 |
Why?
|
| Hydralazine | 2 | 2016 | 36 | 0.250 |
Why?
|
| Fibrinogen | 1 | 2008 | 887 | 0.250 |
Why?
|
| Helicobacter Infections | 1 | 2008 | 386 | 0.250 |
Why?
|
| Hypertension, Pulmonary | 5 | 2020 | 1570 | 0.250 |
Why?
|
| Morpholines | 3 | 2013 | 583 | 0.250 |
Why?
|
| Shock | 2 | 2018 | 318 | 0.240 |
Why?
|
| Isosorbide Dinitrate | 2 | 2016 | 37 | 0.240 |
Why?
|
| Hospitals, Veterans | 3 | 2017 | 398 | 0.240 |
Why?
|
| Specialization | 2 | 2022 | 779 | 0.240 |
Why?
|
| Hyperlipoproteinemia Type II | 2 | 2020 | 396 | 0.240 |
Why?
|
| Histidine | 1 | 2005 | 311 | 0.240 |
Why?
|
| India | 6 | 2023 | 2346 | 0.240 |
Why?
|
| Yin-Yang | 1 | 2004 | 11 | 0.240 |
Why?
|
| Delivery of Health Care, Integrated | 3 | 2018 | 936 | 0.240 |
Why?
|
| Adolescent | 28 | 2021 | 87747 | 0.240 |
Why?
|
| Postoperative Period | 6 | 2020 | 1821 | 0.240 |
Why?
|
| Burns, Electric | 1 | 2004 | 40 | 0.240 |
Why?
|
| Naphthyridines | 2 | 2022 | 141 | 0.230 |
Why?
|
| New Zealand | 4 | 2018 | 355 | 0.230 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2006 | 321 | 0.230 |
Why?
|
| Immunoglobulin G | 1 | 2016 | 4546 | 0.230 |
Why?
|
| Quebec | 2 | 2017 | 142 | 0.230 |
Why?
|
| Marijuana Abuse | 2 | 2018 | 411 | 0.230 |
Why?
|
| Ultrasonography | 7 | 2021 | 5960 | 0.230 |
Why?
|
| Data Interpretation, Statistical | 5 | 2020 | 2696 | 0.230 |
Why?
|
| Autopsy | 2 | 2018 | 1007 | 0.230 |
Why?
|
| Oxidative Stress | 3 | 2019 | 3107 | 0.230 |
Why?
|
| Chronic Disease | 13 | 2024 | 9283 | 0.230 |
Why?
|
| Contrast Media | 5 | 2022 | 5301 | 0.230 |
Why?
|
| Intraoperative Period | 3 | 2017 | 516 | 0.230 |
Why?
|
| Emergency Treatment | 2 | 2019 | 498 | 0.230 |
Why?
|
| Hyperglycemia | 3 | 2020 | 1380 | 0.220 |
Why?
|
| Tyrosine | 4 | 2005 | 1440 | 0.220 |
Why?
|
| Medically Uninsured | 6 | 2021 | 843 | 0.220 |
Why?
|
| Reoperation | 9 | 2021 | 4292 | 0.220 |
Why?
|
| Lymphocyte Count | 1 | 2006 | 780 | 0.220 |
Why?
|
| Early Termination of Clinical Trials | 2 | 2021 | 71 | 0.220 |
Why?
|
| Air Pollution | 3 | 2023 | 2316 | 0.220 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 1 | 2004 | 149 | 0.220 |
Why?
|
| Meta-Analysis as Topic | 1 | 2008 | 1375 | 0.220 |
Why?
|
| Emergencies | 2 | 2020 | 1217 | 0.220 |
Why?
|
| Tachycardia | 2 | 2016 | 603 | 0.210 |
Why?
|
| Apolipoproteins B | 3 | 2022 | 388 | 0.210 |
Why?
|
| Case-Control Studies | 18 | 2022 | 22041 | 0.210 |
Why?
|
| Lung Diseases | 3 | 2022 | 1915 | 0.210 |
Why?
|
| Drug Carriers | 2 | 2019 | 706 | 0.210 |
Why?
|
| Catheterization | 4 | 2020 | 1432 | 0.210 |
Why?
|
| Pyrroles | 7 | 2024 | 1137 | 0.210 |
Why?
|
| Exercise | 4 | 2023 | 5783 | 0.210 |
Why?
|
| Simvastatin | 1 | 2005 | 352 | 0.200 |
Why?
|
| Informed Consent | 2 | 2020 | 1007 | 0.200 |
Why?
|
| Sodium | 6 | 2022 | 1601 | 0.200 |
Why?
|
| Ankle Brachial Index | 4 | 2018 | 163 | 0.200 |
Why?
|
| Publishing | 2 | 2020 | 837 | 0.200 |
Why?
|
| Sympathetic Nervous System | 2 | 2015 | 519 | 0.200 |
Why?
|
| Pain Clinics | 1 | 2021 | 51 | 0.200 |
Why?
|
| Continuous Positive Airway Pressure | 3 | 2017 | 576 | 0.200 |
Why?
|
| Massachusetts | 6 | 2021 | 8805 | 0.200 |
Why?
|
| Atrioventricular Block | 1 | 2023 | 121 | 0.200 |
Why?
|
| Skilled Nursing Facilities | 6 | 2021 | 398 | 0.200 |
Why?
|
| Metabolic Diseases | 2 | 2024 | 685 | 0.200 |
Why?
|
| Aldosterone | 2 | 2023 | 868 | 0.200 |
Why?
|
| Fibric Acids | 1 | 2021 | 29 | 0.200 |
Why?
|
| Kidney Transplantation | 1 | 2017 | 4215 | 0.200 |
Why?
|
| Genetic Loci | 4 | 2019 | 2618 | 0.200 |
Why?
|
| International Normalized Ratio | 4 | 2023 | 387 | 0.200 |
Why?
|
| Immunoglobulin Fragments | 1 | 2021 | 85 | 0.190 |
Why?
|
| Socioeconomic Factors | 10 | 2022 | 7803 | 0.190 |
Why?
|
| Pharmacists | 1 | 2024 | 259 | 0.190 |
Why?
|
| Overweight | 6 | 2022 | 2421 | 0.190 |
Why?
|
| Host-Pathogen Interactions | 2 | 2020 | 1447 | 0.190 |
Why?
|
| Vasodilation | 2 | 2013 | 964 | 0.190 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2023 | 124 | 0.190 |
Why?
|
| Reperfusion | 2 | 2020 | 271 | 0.190 |
Why?
|
| Quality of Life | 11 | 2024 | 13300 | 0.190 |
Why?
|
| Urban Population | 3 | 2020 | 2021 | 0.190 |
Why?
|
| Decision Support Techniques | 3 | 2020 | 2002 | 0.190 |
Why?
|
| Varicose Veins | 1 | 2003 | 155 | 0.190 |
Why?
|
| Pulmonary Artery | 4 | 2020 | 1919 | 0.190 |
Why?
|
| Epoprostenol | 2 | 2012 | 248 | 0.190 |
Why?
|
| Stem Cells | 2 | 2022 | 3525 | 0.190 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2005 | 625 | 0.190 |
Why?
|
| Atrial Function, Left | 2 | 2020 | 186 | 0.190 |
Why?
|
| National Library of Medicine (U.S.) | 1 | 2020 | 35 | 0.180 |
Why?
|
| Brachiocephalic Trunk | 1 | 2020 | 41 | 0.180 |
Why?
|
| Particulate Matter | 3 | 2023 | 2558 | 0.180 |
Why?
|
| Animals | 30 | 2024 | 167940 | 0.180 |
Why?
|
| Ohio | 12 | 2013 | 333 | 0.180 |
Why?
|
| Gram-Negative Anaerobic Bacteria | 1 | 2020 | 16 | 0.180 |
Why?
|
| Receptors, Thrombin | 2 | 2011 | 132 | 0.180 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2021 | 108 | 0.180 |
Why?
|
| Niacin | 1 | 2021 | 119 | 0.180 |
Why?
|
| Premedication | 5 | 2005 | 253 | 0.180 |
Why?
|
| Emergency Service, Hospital | 9 | 2021 | 7809 | 0.180 |
Why?
|
| Regression Analysis | 6 | 2016 | 6361 | 0.180 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2024 | 1724 | 0.180 |
Why?
|
| Internationality | 5 | 2019 | 1005 | 0.180 |
Why?
|
| Pituitary-Adrenal System | 1 | 2023 | 550 | 0.180 |
Why?
|
| Radiography | 9 | 2014 | 6965 | 0.180 |
Why?
|
| Cholesterol, VLDL | 1 | 2020 | 71 | 0.180 |
Why?
|
| Peptic Ulcer | 2 | 2019 | 219 | 0.180 |
Why?
|
| Suture Techniques | 2 | 2003 | 788 | 0.180 |
Why?
|
| Urban Health | 1 | 2003 | 533 | 0.180 |
Why?
|
| Insurance | 1 | 2021 | 114 | 0.180 |
Why?
|
| Models, Economic | 4 | 2018 | 719 | 0.170 |
Why?
|
| Mobility Limitation | 2 | 2021 | 402 | 0.170 |
Why?
|
| Hemostatics | 1 | 2003 | 243 | 0.170 |
Why?
|
| Galactosamine | 1 | 2019 | 27 | 0.170 |
Why?
|
| Certification | 3 | 2019 | 423 | 0.170 |
Why?
|
| Cardiac Pacing, Artificial | 2 | 2023 | 865 | 0.170 |
Why?
|
| Leuprolide | 1 | 2021 | 315 | 0.170 |
Why?
|
| Mustard Plant | 1 | 2019 | 14 | 0.170 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2023 | 698 | 0.170 |
Why?
|
| Quinazolinones | 2 | 2012 | 223 | 0.170 |
Why?
|
| Arteriovenous Fistula | 1 | 2022 | 314 | 0.170 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2020 | 107 | 0.170 |
Why?
|
| Survivors | 5 | 2023 | 2367 | 0.170 |
Why?
|
| Anterior Wall Myocardial Infarction | 1 | 2020 | 43 | 0.170 |
Why?
|
| Friends | 1 | 2020 | 150 | 0.170 |
Why?
|
| Hemostatic Techniques | 2 | 2012 | 114 | 0.170 |
Why?
|
| Histamine H2 Antagonists | 2 | 2010 | 167 | 0.170 |
Why?
|
| Product Labeling | 1 | 2020 | 77 | 0.170 |
Why?
|
| Insurance Carriers | 1 | 2021 | 156 | 0.160 |
Why?
|
| Climatic Processes | 1 | 2018 | 4 | 0.160 |
Why?
|
| Drug Costs | 3 | 2020 | 1184 | 0.160 |
Why?
|
| Reproducibility of Results | 18 | 2021 | 20048 | 0.160 |
Why?
|
| Patients | 2 | 2023 | 906 | 0.160 |
Why?
|
| Patents as Topic | 1 | 2020 | 112 | 0.160 |
Why?
|
| Methylamines | 1 | 2020 | 138 | 0.160 |
Why?
|
| Glucosyltransferases | 1 | 2019 | 96 | 0.160 |
Why?
|
| Polymers | 4 | 2020 | 1620 | 0.160 |
Why?
|
| Breast Implantation | 1 | 2022 | 223 | 0.160 |
Why?
|
| Necrosis | 3 | 2008 | 1612 | 0.160 |
Why?
|
| Homocysteine | 1 | 2022 | 640 | 0.160 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2019 | 114 | 0.160 |
Why?
|
| Proprotein Convertases | 2 | 2022 | 97 | 0.160 |
Why?
|
| Centralized Hospital Services | 1 | 2018 | 19 | 0.160 |
Why?
|
| Embolism, Paradoxical | 1 | 2019 | 55 | 0.160 |
Why?
|
| Hospital Bed Capacity | 3 | 2017 | 210 | 0.160 |
Why?
|
| Budgets | 1 | 2020 | 230 | 0.160 |
Why?
|
| Mitral Valve Prolapse | 1 | 2020 | 215 | 0.160 |
Why?
|
| Interleukin-10 | 1 | 2004 | 1174 | 0.160 |
Why?
|
| Inflammation Mediators | 2 | 2024 | 1882 | 0.160 |
Why?
|
| Fibrosis | 2 | 2023 | 2042 | 0.160 |
Why?
|
| Health Expenditures | 4 | 2021 | 2359 | 0.160 |
Why?
|
| Diet | 3 | 2022 | 8008 | 0.160 |
Why?
|
| Amiodarone | 1 | 2020 | 218 | 0.160 |
Why?
|
| Menopause, Premature | 1 | 2019 | 125 | 0.160 |
Why?
|
| Probability | 7 | 2018 | 2476 | 0.160 |
Why?
|
| Computer Simulation | 6 | 2021 | 6210 | 0.160 |
Why?
|
| Lipoprotein Lipase | 1 | 2019 | 134 | 0.160 |
Why?
|
| Income | 2 | 2022 | 1876 | 0.160 |
Why?
|
| Patient Care | 2 | 2022 | 624 | 0.160 |
Why?
|
| Random Allocation | 4 | 2019 | 2394 | 0.150 |
Why?
|
| Thromboxanes | 2 | 2008 | 47 | 0.150 |
Why?
|
| Communication | 2 | 2024 | 3846 | 0.150 |
Why?
|
| Ventricular Fibrillation | 2 | 2022 | 539 | 0.150 |
Why?
|
| Insulin-Secreting Cells | 3 | 2015 | 907 | 0.150 |
Why?
|
| Gastrointestinal Agents | 1 | 2023 | 509 | 0.150 |
Why?
|
| Dissection | 1 | 2020 | 298 | 0.150 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2024 | 4357 | 0.150 |
Why?
|
| Drug Dosage Calculations | 1 | 2018 | 118 | 0.150 |
Why?
|
| Granulocytes | 1 | 2020 | 551 | 0.150 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2020 | 238 | 0.150 |
Why?
|
| Uncertainty | 2 | 2021 | 754 | 0.150 |
Why?
|
| Calcinosis | 2 | 2019 | 1478 | 0.150 |
Why?
|
| Washington | 1 | 2018 | 312 | 0.150 |
Why?
|
| Patient Participation | 3 | 2021 | 1437 | 0.150 |
Why?
|
| Clinical Trials Data Monitoring Committees | 1 | 2018 | 26 | 0.150 |
Why?
|
| Apolipoprotein C-III | 1 | 2019 | 209 | 0.150 |
Why?
|
| Echocardiography, Doppler, Color | 2 | 2017 | 354 | 0.150 |
Why?
|
| International Classification of Diseases | 2 | 2021 | 884 | 0.150 |
Why?
|
| Sus scrofa | 5 | 2020 | 432 | 0.150 |
Why?
|
| Symporters | 1 | 2020 | 361 | 0.150 |
Why?
|
| Government Programs | 1 | 2020 | 280 | 0.150 |
Why?
|
| Echocardiography, Doppler | 2 | 2019 | 900 | 0.150 |
Why?
|
| Calcium | 2 | 2021 | 5726 | 0.150 |
Why?
|
| Models, Biological | 4 | 2021 | 9468 | 0.150 |
Why?
|
| Advisory Committees | 3 | 2017 | 789 | 0.150 |
Why?
|
| Glucose Tolerance Test | 2 | 2018 | 1174 | 0.150 |
Why?
|
| Duodenum | 1 | 2021 | 486 | 0.150 |
Why?
|
| Continuity of Patient Care | 3 | 2020 | 1067 | 0.150 |
Why?
|
| Drug Therapy | 1 | 2021 | 504 | 0.150 |
Why?
|
| Germany | 5 | 2023 | 875 | 0.150 |
Why?
|
| Alanine Transaminase | 1 | 2020 | 607 | 0.150 |
Why?
|
| Databases as Topic | 2 | 2018 | 474 | 0.150 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 250 | 0.150 |
Why?
|
| Drug Utilization Review | 3 | 2016 | 251 | 0.140 |
Why?
|
| Extracorporeal Membrane Oxygenation | 3 | 2020 | 1455 | 0.140 |
Why?
|
| Reperfusion Injury | 1 | 2024 | 1023 | 0.140 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2023 | 572 | 0.140 |
Why?
|
| Comprehensive Health Care | 1 | 2018 | 124 | 0.140 |
Why?
|
| Mycoses | 1 | 2020 | 387 | 0.140 |
Why?
|
| Public Health | 2 | 2020 | 2655 | 0.140 |
Why?
|
| Single Person | 1 | 2017 | 32 | 0.140 |
Why?
|
| Heart Function Tests | 1 | 2018 | 319 | 0.140 |
Why?
|
| Rehabilitation Centers | 1 | 2019 | 248 | 0.140 |
Why?
|
| Virus Diseases | 1 | 2023 | 721 | 0.140 |
Why?
|
| Models, Statistical | 5 | 2021 | 5073 | 0.140 |
Why?
|
| Hospitals, State | 1 | 2016 | 29 | 0.140 |
Why?
|
| Preoperative Care | 5 | 2021 | 2255 | 0.140 |
Why?
|
| Dosage Forms | 1 | 2017 | 57 | 0.140 |
Why?
|
| Hyperthermia, Induced | 1 | 2021 | 415 | 0.140 |
Why?
|
| Hospitals, University | 1 | 2019 | 568 | 0.140 |
Why?
|
| Natriuretic Peptides | 1 | 2018 | 156 | 0.140 |
Why?
|
| Benzamidines | 3 | 2001 | 23 | 0.140 |
Why?
|
| Cardiac Valve Annuloplasty | 1 | 2017 | 51 | 0.140 |
Why?
|
| Hypotension | 2 | 2020 | 883 | 0.140 |
Why?
|
| Vascular Resistance | 3 | 2013 | 932 | 0.140 |
Why?
|
| Extremities | 2 | 2020 | 867 | 0.140 |
Why?
|
| Sulfonamides | 4 | 2014 | 1973 | 0.140 |
Why?
|
| Insulin | 8 | 2023 | 6592 | 0.140 |
Why?
|
| Heart Valves | 1 | 2018 | 285 | 0.140 |
Why?
|
| Clinical Coding | 1 | 2018 | 181 | 0.140 |
Why?
|
| beta Carotene | 1 | 2018 | 524 | 0.140 |
Why?
|
| Home Care Services | 3 | 2019 | 653 | 0.140 |
Why?
|
| Point-of-Care Systems | 2 | 2021 | 1208 | 0.140 |
Why?
|
| Review Literature as Topic | 1 | 2018 | 350 | 0.140 |
Why?
|
| Neovascularization, Physiologic | 3 | 2022 | 1335 | 0.140 |
Why?
|
| Interleukin-1beta | 1 | 2022 | 999 | 0.140 |
Why?
|
| Uric Acid | 2 | 2020 | 807 | 0.140 |
Why?
|
| ABO Blood-Group System | 1 | 2019 | 369 | 0.130 |
Why?
|
| Neurology | 1 | 2024 | 779 | 0.130 |
Why?
|
| Genotype | 10 | 2020 | 12959 | 0.130 |
Why?
|
| Thiazolidines | 1 | 2016 | 69 | 0.130 |
Why?
|
| Carotid Artery, Internal | 3 | 2021 | 438 | 0.130 |
Why?
|
| Long-Term Care | 2 | 2015 | 628 | 0.130 |
Why?
|
| Hyperuricemia | 1 | 2019 | 224 | 0.130 |
Why?
|
| Receptors, LDL | 1 | 2019 | 491 | 0.130 |
Why?
|
| Trust | 1 | 2021 | 528 | 0.130 |
Why?
|
| Ventricular Function, Right | 1 | 2020 | 610 | 0.130 |
Why?
|
| Critical Illness | 2 | 2020 | 2709 | 0.130 |
Why?
|
| Paresis | 1 | 2017 | 177 | 0.130 |
Why?
|
| Hobbies | 1 | 2015 | 6 | 0.130 |
Why?
|
| Oligopeptides | 1 | 2021 | 1188 | 0.130 |
Why?
|
| New York | 1 | 2018 | 874 | 0.130 |
Why?
|
| Transplantation, Autologous | 2 | 2018 | 2120 | 0.130 |
Why?
|
| Polymorphism, Single Nucleotide | 7 | 2020 | 15766 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2022 | 20484 | 0.130 |
Why?
|
| Nitrates | 1 | 2017 | 264 | 0.130 |
Why?
|
| Equipment Design | 8 | 2018 | 3520 | 0.130 |
Why?
|
| Bundle-Branch Block | 2 | 2022 | 281 | 0.130 |
Why?
|
| Anemia, Sickle Cell | 1 | 2024 | 1056 | 0.130 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2017 | 192 | 0.130 |
Why?
|
| Monitoring, Physiologic | 2 | 2021 | 1784 | 0.130 |
Why?
|
| Thailand | 1 | 2016 | 289 | 0.130 |
Why?
|
| Medicare Part C | 1 | 2020 | 322 | 0.130 |
Why?
|
| Connective Tissue Diseases | 1 | 2018 | 286 | 0.130 |
Why?
|
| Caffeine | 1 | 2020 | 701 | 0.130 |
Why?
|
| Fluorescein Angiography | 1 | 2020 | 1045 | 0.130 |
Why?
|
| Body Weight | 3 | 2023 | 4613 | 0.120 |
Why?
|
| Magnetic Resonance Imaging, Cine | 2 | 2019 | 1038 | 0.120 |
Why?
|
| Sample Size | 2 | 2016 | 840 | 0.120 |
Why?
|
| Intermittent Claudication | 3 | 2014 | 305 | 0.120 |
Why?
|
| Oximes | 3 | 2001 | 306 | 0.120 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2019 | 516 | 0.120 |
Why?
|
| Prosthesis-Related Infections | 1 | 2020 | 486 | 0.120 |
Why?
|
| Standard of Care | 2 | 2021 | 552 | 0.120 |
Why?
|
| Recreation | 1 | 2015 | 120 | 0.120 |
Why?
|
| Digoxin | 1 | 2016 | 247 | 0.120 |
Why?
|
| Financial Management | 1 | 2016 | 161 | 0.120 |
Why?
|
| Self Care | 1 | 2020 | 793 | 0.120 |
Why?
|
| HIV Infections | 2 | 2020 | 17159 | 0.120 |
Why?
|
| Herb-Drug Interactions | 1 | 2014 | 10 | 0.120 |
Why?
|
| Pharyngitis | 1 | 2016 | 220 | 0.120 |
Why?
|
| Vascular System Injuries | 1 | 2018 | 248 | 0.120 |
Why?
|
| Brazil | 2 | 2016 | 1214 | 0.120 |
Why?
|
| Heart Failure, Systolic | 1 | 2016 | 136 | 0.120 |
Why?
|
| Beverages | 1 | 2020 | 819 | 0.120 |
Why?
|
| Pyrrolidines | 3 | 2001 | 338 | 0.120 |
Why?
|
| Medicare Part D | 2 | 2016 | 354 | 0.120 |
Why?
|
| Lactones | 2 | 2018 | 319 | 0.120 |
Why?
|
| Patient Transfer | 2 | 2018 | 778 | 0.120 |
Why?
|
| Disease-Free Survival | 6 | 2019 | 6830 | 0.120 |
Why?
|
| Cocaine-Related Disorders | 1 | 2018 | 460 | 0.120 |
Why?
|
| Ischemic Postconditioning | 1 | 2014 | 25 | 0.120 |
Why?
|
| Positron-Emission Tomography | 6 | 2023 | 6457 | 0.120 |
Why?
|
| Policy Making | 1 | 2018 | 539 | 0.120 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 749 | 0.120 |
Why?
|
| Gastroepiploic Artery | 1 | 2014 | 3 | 0.120 |
Why?
|
| Molecular Targeted Therapy | 2 | 2017 | 2805 | 0.120 |
Why?
|
| Breathing Exercises | 1 | 2014 | 60 | 0.120 |
Why?
|
| Qualitative Research | 2 | 2022 | 2958 | 0.120 |
Why?
|
| Electric Conductivity | 5 | 2014 | 409 | 0.120 |
Why?
|
| Radiosurgery | 1 | 2024 | 1343 | 0.120 |
Why?
|
| Radiation Injuries | 1 | 2022 | 1183 | 0.120 |
Why?
|
| Transportation of Patients | 1 | 2015 | 176 | 0.120 |
Why?
|
| Genome-Wide Association Study | 7 | 2020 | 12602 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2022 | 36247 | 0.120 |
Why?
|
| Hypertension, Renovascular | 1 | 2014 | 117 | 0.120 |
Why?
|
| Tricuspid Valve | 1 | 2017 | 409 | 0.120 |
Why?
|
| Biological Transport | 1 | 2018 | 2087 | 0.120 |
Why?
|
| Food, Organic | 1 | 2014 | 35 | 0.120 |
Why?
|
| Asia | 4 | 2017 | 618 | 0.110 |
Why?
|
| Rhabdomyolysis | 2 | 2018 | 155 | 0.110 |
Why?
|
| Longitudinal Studies | 9 | 2024 | 14482 | 0.110 |
Why?
|
| Remission Induction | 4 | 2020 | 2394 | 0.110 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2018 | 498 | 0.110 |
Why?
|
| Medical Record Linkage | 1 | 2015 | 289 | 0.110 |
Why?
|
| Dipyridamole | 2 | 2007 | 143 | 0.110 |
Why?
|
| Alanine | 3 | 2001 | 607 | 0.110 |
Why?
|
| Intestinal Diseases | 1 | 2018 | 507 | 0.110 |
Why?
|
| Brachytherapy | 2 | 2017 | 1240 | 0.110 |
Why?
|
| Nitroglycerin | 1 | 2015 | 329 | 0.110 |
Why?
|
| Aorta, Thoracic | 3 | 2023 | 1097 | 0.110 |
Why?
|
| Poisson Distribution | 1 | 2015 | 507 | 0.110 |
Why?
|
| Filtration | 2 | 2005 | 229 | 0.110 |
Why?
|
| Diarrhea | 1 | 2020 | 1341 | 0.110 |
Why?
|
| Balloon Occlusion | 2 | 2005 | 127 | 0.110 |
Why?
|
| Motor Skills | 1 | 2017 | 520 | 0.110 |
Why?
|
| Aircraft | 1 | 2014 | 126 | 0.110 |
Why?
|
| Intubation, Intratracheal | 1 | 2021 | 1328 | 0.110 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2019 | 2007 | 0.110 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2016 | 629 | 0.110 |
Why?
|
| Attitude of Health Personnel | 3 | 2021 | 3870 | 0.110 |
Why?
|
| Interleukin-17 | 1 | 2019 | 908 | 0.110 |
Why?
|
| Ventricular Dysfunction | 1 | 2014 | 145 | 0.110 |
Why?
|
| Microcirculation | 1 | 2018 | 1279 | 0.110 |
Why?
|
| Cell Membrane | 2 | 2021 | 3683 | 0.110 |
Why?
|
| Central Nervous System Diseases | 1 | 2018 | 521 | 0.110 |
Why?
|
| Boston | 4 | 2019 | 9282 | 0.110 |
Why?
|
| China | 5 | 2020 | 2340 | 0.110 |
Why?
|
| Peroxynitrous Acid | 2 | 2024 | 42 | 0.110 |
Why?
|
| Clinical Protocols | 4 | 2017 | 1439 | 0.110 |
Why?
|
| Aneurysm, Ruptured | 1 | 2018 | 460 | 0.110 |
Why?
|
| Respiratory Tract Diseases | 1 | 2019 | 747 | 0.110 |
Why?
|
| Macular Degeneration | 1 | 2020 | 1003 | 0.110 |
Why?
|
| Triage | 1 | 2020 | 982 | 0.110 |
Why?
|
| Cocaine | 1 | 2018 | 961 | 0.110 |
Why?
|
| Life Expectancy | 2 | 2018 | 1249 | 0.110 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2014 | 135 | 0.110 |
Why?
|
| Scimitar Syndrome | 1 | 2013 | 31 | 0.110 |
Why?
|
| Neutrophils | 1 | 2006 | 3770 | 0.110 |
Why?
|
| Suction | 1 | 2014 | 263 | 0.110 |
Why?
|
| Drug Synergism | 2 | 2009 | 1755 | 0.110 |
Why?
|
| Heparin, Low-Molecular-Weight | 3 | 2008 | 346 | 0.110 |
Why?
|
| Cost Savings | 1 | 2018 | 920 | 0.110 |
Why?
|
| Morphine | 1 | 2017 | 656 | 0.110 |
Why?
|
| Professional Review Organizations | 1 | 2012 | 49 | 0.100 |
Why?
|
| Corn Oil | 2 | 2023 | 30 | 0.100 |
Why?
|
| Natural Language Processing | 1 | 2021 | 1136 | 0.100 |
Why?
|
| Cost of Illness | 3 | 2011 | 1940 | 0.100 |
Why?
|
| Models, Animal | 5 | 2020 | 2117 | 0.100 |
Why?
|
| Hot Temperature | 1 | 2019 | 1435 | 0.100 |
Why?
|
| Inflammasomes | 1 | 2017 | 532 | 0.100 |
Why?
|
| CD40 Ligand | 2 | 2012 | 522 | 0.100 |
Why?
|
| Liver Diseases | 2 | 2019 | 1301 | 0.100 |
Why?
|
| Four-Dimensional Computed Tomography | 3 | 2020 | 144 | 0.100 |
Why?
|
| Life Support Care | 1 | 2014 | 222 | 0.100 |
Why?
|
| Intraoperative Complications | 2 | 2013 | 1186 | 0.100 |
Why?
|
| Selection Bias | 1 | 2014 | 358 | 0.100 |
Why?
|
| Program Evaluation | 3 | 2019 | 2494 | 0.100 |
Why?
|
| Health Care Surveys | 2 | 2017 | 2434 | 0.100 |
Why?
|
| Regional Blood Flow | 2 | 2007 | 1490 | 0.100 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 1791 | 0.100 |
Why?
|
| Groin | 1 | 2012 | 106 | 0.100 |
Why?
|
| beta-Alanine | 1 | 2012 | 82 | 0.100 |
Why?
|
| Carotid Artery, Common | 2 | 2004 | 177 | 0.100 |
Why?
|
| Fatal Outcome | 1 | 2017 | 1833 | 0.100 |
Why?
|
| Lipid Metabolism | 2 | 2018 | 1902 | 0.100 |
Why?
|
| Ghrelin | 1 | 2013 | 252 | 0.100 |
Why?
|
| Government Regulation | 1 | 2016 | 526 | 0.100 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2020 | 973 | 0.100 |
Why?
|
| Respiratory Tract Infections | 2 | 2021 | 1001 | 0.100 |
Why?
|
| Appointments and Schedules | 1 | 2016 | 443 | 0.100 |
Why?
|
| Air Pollutants | 2 | 2020 | 2843 | 0.100 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2014 | 461 | 0.100 |
Why?
|
| Editorial Policies | 1 | 2016 | 457 | 0.100 |
Why?
|
| Vitiligo | 1 | 2012 | 98 | 0.100 |
Why?
|
| Pyrimidinones | 1 | 2014 | 383 | 0.100 |
Why?
|
| Data Mining | 1 | 2016 | 553 | 0.100 |
Why?
|
| Viral Load | 1 | 2020 | 3323 | 0.100 |
Why?
|
| Sulfones | 1 | 2014 | 447 | 0.090 |
Why?
|
| Hospice Care | 1 | 2018 | 692 | 0.090 |
Why?
|
| Comparative Effectiveness Research | 2 | 2014 | 718 | 0.090 |
Why?
|
| Epoetin Alfa | 1 | 2011 | 79 | 0.090 |
Why?
|
| Weight-Bearing | 1 | 2014 | 518 | 0.090 |
Why?
|
| Periplasmic Binding Proteins | 1 | 2011 | 34 | 0.090 |
Why?
|
| Heptanoic Acids | 3 | 2014 | 347 | 0.090 |
Why?
|
| Kidney Function Tests | 5 | 2014 | 680 | 0.090 |
Why?
|
| Heart Ventricles | 2 | 2020 | 3811 | 0.090 |
Why?
|
| Antibodies | 1 | 2019 | 2424 | 0.090 |
Why?
|
| Italy | 2 | 2023 | 840 | 0.090 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2012 | 323 | 0.090 |
Why?
|
| Minnesota | 2 | 2009 | 340 | 0.090 |
Why?
|
| Intestines | 1 | 2020 | 1907 | 0.090 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2012 | 192 | 0.090 |
Why?
|
| Tibial Arteries | 1 | 2011 | 60 | 0.090 |
Why?
|
| Total Quality Management | 1 | 2012 | 264 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2024 | 17766 | 0.090 |
Why?
|
| Pre-Eclampsia | 1 | 2020 | 1230 | 0.090 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2014 | 479 | 0.090 |
Why?
|
| Monocytes | 1 | 2020 | 2574 | 0.090 |
Why?
|
| Interleukin-18 | 1 | 2012 | 251 | 0.090 |
Why?
|
| Monte Carlo Method | 1 | 2016 | 1256 | 0.090 |
Why?
|
| Osteoporotic Fractures | 1 | 2015 | 409 | 0.090 |
Why?
|
| Stomach Ulcer | 1 | 2010 | 123 | 0.090 |
Why?
|
| Electric Injuries | 1 | 1990 | 25 | 0.090 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 2623 | 0.090 |
Why?
|
| Activities of Daily Living | 2 | 2017 | 2414 | 0.090 |
Why?
|
| Benchmarking | 2 | 2019 | 1043 | 0.090 |
Why?
|
| Developed Countries | 2 | 2023 | 443 | 0.090 |
Why?
|
| Communicable Diseases | 1 | 2018 | 879 | 0.090 |
Why?
|
| Reference Values | 5 | 2012 | 4920 | 0.090 |
Why?
|
| Drug Evaluation | 3 | 2007 | 642 | 0.090 |
Why?
|
| Waist Circumference | 2 | 2011 | 922 | 0.090 |
Why?
|
| Pancreatitis | 2 | 2014 | 1100 | 0.090 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2018 | 1811 | 0.090 |
Why?
|
| Injections, Subcutaneous | 2 | 2023 | 679 | 0.090 |
Why?
|
| Patient-Centered Care | 1 | 2020 | 1416 | 0.090 |
Why?
|
| Endothelial Cells | 3 | 2024 | 3537 | 0.090 |
Why?
|
| Decision Trees | 2 | 2011 | 506 | 0.090 |
Why?
|
| Pneumonia, Bacterial | 1 | 2013 | 319 | 0.090 |
Why?
|
| Intestinal Mucosa | 1 | 2021 | 3023 | 0.090 |
Why?
|
| General Surgery | 1 | 2021 | 1681 | 0.090 |
Why?
|
| Embolism, Cholesterol | 1 | 2009 | 33 | 0.080 |
Why?
|
| Galactose | 1 | 2011 | 297 | 0.080 |
Why?
|
| Nephelometry and Turbidimetry | 1 | 2009 | 92 | 0.080 |
Why?
|
| Surgical Procedures, Operative | 1 | 2021 | 1919 | 0.080 |
Why?
|
| Aorta | 1 | 2017 | 2042 | 0.080 |
Why?
|
| Risk Management | 1 | 2013 | 558 | 0.080 |
Why?
|
| Prostheses and Implants | 3 | 2021 | 1272 | 0.080 |
Why?
|
| Head | 1 | 2015 | 922 | 0.080 |
Why?
|
| Biopsy | 2 | 2023 | 6775 | 0.080 |
Why?
|
| Porphyrias | 1 | 2009 | 58 | 0.080 |
Why?
|
| Analgesics | 1 | 2016 | 1066 | 0.080 |
Why?
|
| Markov Chains | 3 | 2024 | 971 | 0.080 |
Why?
|
| Drug Combinations | 4 | 2019 | 2024 | 0.080 |
Why?
|
| Liver | 2 | 2020 | 7512 | 0.080 |
Why?
|
| Brachial Artery | 1 | 2011 | 368 | 0.080 |
Why?
|
| Bacteria | 1 | 2020 | 2196 | 0.080 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2011 | 440 | 0.080 |
Why?
|
| Phosphatidylcholines | 1 | 2010 | 406 | 0.080 |
Why?
|
| Cardiac Output | 1 | 2011 | 837 | 0.080 |
Why?
|
| Area Under Curve | 4 | 2018 | 1635 | 0.080 |
Why?
|
| Melanocytes | 1 | 2012 | 512 | 0.080 |
Why?
|
| Genetics, Population | 1 | 2014 | 929 | 0.080 |
Why?
|
| Patient Preference | 1 | 2016 | 921 | 0.080 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2023 | 2421 | 0.080 |
Why?
|
| Delayed Diagnosis | 1 | 2013 | 463 | 0.080 |
Why?
|
| Perfusion | 2 | 2023 | 1376 | 0.080 |
Why?
|
| Receptors, Glutamate | 1 | 2009 | 229 | 0.080 |
Why?
|
| Adiponectin | 1 | 2014 | 1115 | 0.080 |
Why?
|
| Latin America | 3 | 2017 | 405 | 0.080 |
Why?
|
| Pilot Projects | 5 | 2021 | 8553 | 0.080 |
Why?
|
| Retroperitoneal Space | 2 | 2006 | 173 | 0.080 |
Why?
|
| Lung Neoplasms | 2 | 2023 | 13249 | 0.080 |
Why?
|
| Up-Regulation | 3 | 2024 | 4127 | 0.080 |
Why?
|
| Brain | 3 | 2020 | 26912 | 0.080 |
Why?
|
| Equipment Safety | 3 | 2008 | 253 | 0.080 |
Why?
|
| Journal Impact Factor | 2 | 2020 | 156 | 0.080 |
Why?
|
| Physical Examination | 1 | 2014 | 1244 | 0.070 |
Why?
|
| Biomimetic Materials | 1 | 2009 | 173 | 0.070 |
Why?
|
| Creatine Kinase | 3 | 2024 | 691 | 0.070 |
Why?
|
| Receptors, Metabotropic Glutamate | 1 | 2009 | 196 | 0.070 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2011 | 434 | 0.070 |
Why?
|
| Emigration and Immigration | 1 | 2010 | 395 | 0.070 |
Why?
|
| Pentanoic Acids | 1 | 2007 | 19 | 0.070 |
Why?
|
| Developing Countries | 1 | 2020 | 2880 | 0.070 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2020 | 3335 | 0.070 |
Why?
|
| Cyclic N-Oxides | 1 | 2007 | 73 | 0.070 |
Why?
|
| Body Height | 2 | 2010 | 1570 | 0.070 |
Why?
|
| Angioscopy | 1 | 2007 | 48 | 0.070 |
Why?
|
| Administration, Inhalation | 2 | 2021 | 1156 | 0.070 |
Why?
|
| Genetic Heterogeneity | 1 | 2010 | 724 | 0.070 |
Why?
|
| Glucose Intolerance | 3 | 2018 | 579 | 0.070 |
Why?
|
| Benzimidazoles | 1 | 2012 | 858 | 0.070 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2008 | 138 | 0.070 |
Why?
|
| Age of Onset | 3 | 2021 | 3302 | 0.070 |
Why?
|
| Antithrombin III | 1 | 2007 | 129 | 0.070 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2008 | 152 | 0.070 |
Why?
|
| Perioperative Period | 2 | 2019 | 265 | 0.070 |
Why?
|
| Platelet Adhesiveness | 1 | 2007 | 154 | 0.070 |
Why?
|
| Deglutition Disorders | 1 | 2013 | 627 | 0.070 |
Why?
|
| Testosterone | 1 | 2018 | 2469 | 0.070 |
Why?
|
| Neuromuscular Junction | 1 | 2009 | 406 | 0.070 |
Why?
|
| Internship and Residency | 2 | 2018 | 5867 | 0.070 |
Why?
|
| Computer-Aided Design | 3 | 2015 | 301 | 0.070 |
Why?
|
| Thermography | 1 | 2007 | 63 | 0.070 |
Why?
|
| Energy Metabolism | 1 | 2018 | 2869 | 0.070 |
Why?
|
| England | 2 | 2019 | 526 | 0.070 |
Why?
|
| Disease Models, Animal | 2 | 2024 | 18134 | 0.070 |
Why?
|
| P-Selectin | 2 | 2006 | 600 | 0.070 |
Why?
|
| Rats | 4 | 2022 | 23695 | 0.070 |
Why?
|
| Forced Expiratory Volume | 2 | 2021 | 1810 | 0.070 |
Why?
|
| Early Diagnosis | 3 | 2018 | 1181 | 0.070 |
Why?
|
| Rupture, Spontaneous | 1 | 2007 | 356 | 0.070 |
Why?
|
| Glucagon-Like Peptide 1 | 2 | 2023 | 366 | 0.070 |
Why?
|
| Cell Proliferation | 2 | 2012 | 10434 | 0.070 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2013 | 1215 | 0.070 |
Why?
|
| Calcium-Binding Proteins | 1 | 2011 | 1066 | 0.070 |
Why?
|
| Microfilament Proteins | 2 | 2024 | 1134 | 0.070 |
Why?
|
| Electrophysiology | 2 | 2009 | 1265 | 0.060 |
Why?
|
| Substance-Related Disorders | 2 | 2021 | 4370 | 0.060 |
Why?
|
| Lung | 2 | 2021 | 9989 | 0.060 |
Why?
|
| Cell Adhesion | 1 | 2012 | 3096 | 0.060 |
Why?
|
| Diabetic Retinopathy | 1 | 2015 | 1268 | 0.060 |
Why?
|
| Critical Pathways | 2 | 2023 | 475 | 0.060 |
Why?
|
| Preoperative Period | 2 | 2018 | 555 | 0.060 |
Why?
|
| Focus Groups | 2 | 2021 | 1372 | 0.060 |
Why?
|
| Hydrogen Bonding | 1 | 2005 | 291 | 0.060 |
Why?
|
| Hematocrit | 2 | 2022 | 630 | 0.060 |
Why?
|
| Muscles | 1 | 1990 | 1581 | 0.060 |
Why?
|
| Analgesics, Opioid | 2 | 2022 | 3762 | 0.060 |
Why?
|
| Cells, Cultured | 3 | 2024 | 18968 | 0.060 |
Why?
|
| Crystallography, X-Ray | 2 | 2011 | 1979 | 0.060 |
Why?
|
| Calibration | 2 | 2018 | 816 | 0.060 |
Why?
|
| Wound Healing | 1 | 2016 | 2786 | 0.060 |
Why?
|
| Phantoms, Imaging | 2 | 2014 | 2510 | 0.060 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2007 | 165 | 0.060 |
Why?
|
| Heterozygote | 1 | 2012 | 2797 | 0.060 |
Why?
|
| Bibliometrics | 2 | 2019 | 351 | 0.060 |
Why?
|
| Cell Adhesion Molecules | 2 | 2024 | 1602 | 0.060 |
Why?
|
| Threonine | 1 | 2005 | 272 | 0.060 |
Why?
|
| Vascular Grafting | 2 | 2017 | 153 | 0.060 |
Why?
|
| Graft Rejection | 1 | 2018 | 4423 | 0.060 |
Why?
|
| Epidemiologic Methods | 4 | 2011 | 1344 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2015 | 3726 | 0.060 |
Why?
|
| Hemagglutination Inhibition Tests | 1 | 2024 | 87 | 0.060 |
Why?
|
| Artifacts | 1 | 2013 | 1893 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2018 | 4554 | 0.060 |
Why?
|
| Pipecolic Acids | 1 | 2005 | 78 | 0.060 |
Why?
|
| Chromosome Mapping | 1 | 2013 | 4625 | 0.060 |
Why?
|
| Optics and Photonics | 1 | 2006 | 305 | 0.060 |
Why?
|
| RNA, Messenger | 1 | 2019 | 12762 | 0.060 |
Why?
|
| Patient Compliance | 4 | 2017 | 2689 | 0.060 |
Why?
|
| Internet | 2 | 2014 | 3074 | 0.060 |
Why?
|
| Mendelian Randomization Analysis | 2 | 2020 | 989 | 0.060 |
Why?
|
| Cognition Disorders | 1 | 2018 | 3976 | 0.060 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2009 | 740 | 0.060 |
Why?
|
| Valine | 1 | 2006 | 409 | 0.060 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2018 | 1430 | 0.060 |
Why?
|
| History, 21st Century | 2 | 2021 | 1576 | 0.060 |
Why?
|
| Hemostasis | 1 | 2006 | 468 | 0.060 |
Why?
|
| Catalysis | 1 | 2005 | 775 | 0.060 |
Why?
|
| Thromboxane A2 | 1 | 2003 | 91 | 0.060 |
Why?
|
| Cannabinoids | 1 | 2006 | 173 | 0.060 |
Why?
|
| Benzylamines | 1 | 2005 | 248 | 0.060 |
Why?
|
| Azetidines | 1 | 2005 | 137 | 0.060 |
Why?
|
| Sensitivity and Specificity | 5 | 2021 | 14656 | 0.060 |
Why?
|
| Genetic Variation | 1 | 2019 | 6540 | 0.060 |
Why?
|
| Cross Infection | 1 | 2013 | 1434 | 0.060 |
Why?
|
| Osteoarthritis, Knee | 1 | 2014 | 1234 | 0.060 |
Why?
|
| Japan | 3 | 2017 | 1369 | 0.060 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2024 | 147 | 0.050 |
Why?
|
| Septal Occluder Device | 1 | 2024 | 126 | 0.050 |
Why?
|
| Hyperinsulinism | 1 | 2006 | 398 | 0.050 |
Why?
|
| Medication Therapy Management | 2 | 2016 | 132 | 0.050 |
Why?
|
| Hematologic Agents | 1 | 2003 | 41 | 0.050 |
Why?
|
| Flow Cytometry | 3 | 2009 | 5873 | 0.050 |
Why?
|
| Telemedicine | 1 | 2020 | 3005 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2022 | 5797 | 0.050 |
Why?
|
| Bhutan | 1 | 2023 | 62 | 0.050 |
Why?
|
| Factor XIa | 1 | 2022 | 9 | 0.050 |
Why?
|
| Fractures, Bone | 1 | 2015 | 2041 | 0.050 |
Why?
|
| Sick Sinus Syndrome | 1 | 2023 | 45 | 0.050 |
Why?
|
| Therapeutic Equivalency | 2 | 2019 | 136 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 9388 | 0.050 |
Why?
|
| Protein Conformation | 1 | 2011 | 3969 | 0.050 |
Why?
|
| Educational Status | 1 | 2010 | 2512 | 0.050 |
Why?
|
| Mineralocorticoids | 1 | 2022 | 38 | 0.050 |
Why?
|
| Salicylic Acid | 1 | 2022 | 64 | 0.050 |
Why?
|
| Subtilisins | 1 | 2022 | 82 | 0.050 |
Why?
|
| Software | 1 | 2016 | 4420 | 0.050 |
Why?
|
| Phosphoproteins | 2 | 2024 | 2441 | 0.050 |
Why?
|
| Superior Vena Cava Syndrome | 1 | 2002 | 57 | 0.050 |
Why?
|
| Bone Density | 1 | 2015 | 3528 | 0.050 |
Why?
|
| Polysaccharides | 1 | 2009 | 1016 | 0.050 |
Why?
|
| Feasibility Studies | 3 | 2021 | 5201 | 0.050 |
Why?
|
| Tablets | 1 | 2022 | 149 | 0.050 |
Why?
|
| Capsules | 1 | 2022 | 192 | 0.050 |
Why?
|
| Fluoroscopy | 2 | 2021 | 943 | 0.050 |
Why?
|
| Ramipril | 1 | 2022 | 97 | 0.050 |
Why?
|
| DNA | 1 | 2016 | 7236 | 0.050 |
Why?
|
| Carotid Artery, External | 1 | 2001 | 38 | 0.050 |
Why?
|
| Health Status Indicators | 1 | 2007 | 968 | 0.050 |
Why?
|
| Patient Satisfaction | 1 | 2014 | 3451 | 0.050 |
Why?
|
| Drosophila | 1 | 2009 | 1492 | 0.050 |
Why?
|
| Heme Oxygenase-1 | 1 | 2024 | 364 | 0.050 |
Why?
|
| Beds | 1 | 2021 | 48 | 0.050 |
Why?
|
| Research Support as Topic | 2 | 2017 | 699 | 0.050 |
Why?
|
| Ultrasonography, Doppler, Duplex | 2 | 2018 | 200 | 0.050 |
Why?
|
| Sclerotherapy | 1 | 2003 | 181 | 0.050 |
Why?
|
| Platelet Count | 2 | 2018 | 777 | 0.050 |
Why?
|
| Sampling Studies | 1 | 2003 | 614 | 0.050 |
Why?
|
| Scattering, Small Angle | 1 | 2021 | 64 | 0.050 |
Why?
|
| Dependent Ambulation | 1 | 2021 | 12 | 0.050 |
Why?
|
| New York City | 2 | 2019 | 723 | 0.050 |
Why?
|
| Zinc | 1 | 2005 | 690 | 0.050 |
Why?
|
| Receptors, Mineralocorticoid | 1 | 2022 | 164 | 0.050 |
Why?
|
| Whole Blood Coagulation Time | 1 | 2001 | 31 | 0.050 |
Why?
|
| Feeding Behavior | 1 | 2013 | 3185 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2007 | 3531 | 0.050 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2024 | 704 | 0.050 |
Why?
|
| Professional Role | 1 | 2024 | 311 | 0.050 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2005 | 915 | 0.050 |
Why?
|
| Bandages | 1 | 2003 | 270 | 0.050 |
Why?
|
| Amino Acid Substitution | 1 | 2005 | 1737 | 0.050 |
Why?
|
| Arginine | 1 | 2005 | 934 | 0.050 |
Why?
|
| Linoleic Acid | 1 | 2022 | 159 | 0.050 |
Why?
|
| Psychomotor Agitation | 1 | 2023 | 306 | 0.050 |
Why?
|
| Axillary Artery | 1 | 2020 | 48 | 0.050 |
Why?
|
| Basilar Artery | 1 | 2022 | 205 | 0.050 |
Why?
|
| Receptors, CXCR4 | 1 | 2005 | 728 | 0.050 |
Why?
|
| X-Ray Diffraction | 1 | 2021 | 420 | 0.050 |
Why?
|
| Aging | 1 | 2019 | 8641 | 0.050 |
Why?
|
| Esters | 1 | 2021 | 211 | 0.050 |
Why?
|
| Administration, Cutaneous | 1 | 2003 | 711 | 0.040 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2024 | 1128 | 0.040 |
Why?
|
| Food-Drug Interactions | 1 | 2020 | 25 | 0.040 |
Why?
|
| Placebo Effect | 2 | 2018 | 511 | 0.040 |
Why?
|
| Monocrotaline | 1 | 2020 | 27 | 0.040 |
Why?
|
| Cell Movement | 1 | 2012 | 5206 | 0.040 |
Why?
|
| Vaccines, Inactivated | 1 | 2021 | 180 | 0.040 |
Why?
|
| User-Computer Interface | 1 | 2007 | 1402 | 0.040 |
Why?
|
| Equipment and Supplies | 1 | 2003 | 275 | 0.040 |
Why?
|
| Hemorrhagic Disorders | 1 | 2020 | 35 | 0.040 |
Why?
|
| Sulfhydryl Compounds | 1 | 2021 | 299 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2020 | 6242 | 0.040 |
Why?
|
| Neprilysin | 1 | 2023 | 472 | 0.040 |
Why?
|
| Vertebrobasilar Insufficiency | 1 | 2001 | 112 | 0.040 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2021 | 227 | 0.040 |
Why?
|
| Pericardiocentesis | 1 | 2020 | 79 | 0.040 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2005 | 1067 | 0.040 |
Why?
|
| Quality Control | 2 | 2014 | 827 | 0.040 |
Why?
|
| Swine | 3 | 2017 | 5902 | 0.040 |
Why?
|
| Intraoperative Care | 1 | 2003 | 768 | 0.040 |
Why?
|
| Models, Molecular | 2 | 2011 | 5429 | 0.040 |
Why?
|
| Cobalt | 1 | 2020 | 155 | 0.040 |
Why?
|
| Prescriptions | 1 | 2022 | 388 | 0.040 |
Why?
|
| Publication Bias | 1 | 2020 | 162 | 0.040 |
Why?
|
| Tetraploidy | 1 | 2019 | 29 | 0.040 |
Why?
|
| Ultrasonics | 1 | 2020 | 207 | 0.040 |
Why?
|
| Vasculitis | 1 | 2004 | 523 | 0.040 |
Why?
|
| Vitamin B 12 Deficiency | 1 | 2020 | 119 | 0.040 |
Why?
|
| Fish Oils | 1 | 2023 | 482 | 0.040 |
Why?
|
| Child | 3 | 2020 | 79758 | 0.040 |
Why?
|
| Chromium | 1 | 2020 | 132 | 0.040 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2022 | 263 | 0.040 |
Why?
|
| Blood Cell Count | 1 | 2020 | 398 | 0.040 |
Why?
|
| X-Ray Microtomography | 1 | 2021 | 444 | 0.040 |
Why?
|
| Pericardium | 1 | 2023 | 675 | 0.040 |
Why?
|
| Interleukins | 1 | 2004 | 782 | 0.040 |
Why?
|
| Amides | 1 | 2021 | 448 | 0.040 |
Why?
|
| Hyperparathyroidism | 1 | 2020 | 339 | 0.040 |
Why?
|
| Information Systems | 1 | 2021 | 398 | 0.040 |
Why?
|
| Mexico | 2 | 2012 | 760 | 0.040 |
Why?
|
| Rain | 1 | 2018 | 61 | 0.040 |
Why?
|
| Michigan | 1 | 2019 | 342 | 0.040 |
Why?
|
| Vital Capacity | 1 | 2021 | 965 | 0.040 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2022 | 542 | 0.040 |
Why?
|
| Freedom | 1 | 2018 | 70 | 0.040 |
Why?
|
| Malaysia | 1 | 2018 | 107 | 0.040 |
Why?
|
| Neurologic Examination | 2 | 2016 | 916 | 0.040 |
Why?
|
| Emergency Medicine | 1 | 2008 | 1195 | 0.040 |
Why?
|
| Matched-Pair Analysis | 1 | 2019 | 284 | 0.040 |
Why?
|
| Alloys | 3 | 2004 | 113 | 0.040 |
Why?
|
| North Carolina | 1 | 2019 | 325 | 0.040 |
Why?
|
| Policy | 1 | 2022 | 511 | 0.040 |
Why?
|
| Insurance Claim Review | 2 | 2015 | 737 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2021 | 11341 | 0.040 |
Why?
|
| Gene Expression Regulation, Plant | 1 | 2019 | 212 | 0.040 |
Why?
|
| Societies, Scientific | 1 | 2019 | 221 | 0.040 |
Why?
|
| Risk Adjustment | 1 | 2022 | 601 | 0.040 |
Why?
|
| Rats, Wistar | 1 | 2022 | 1849 | 0.040 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2020 | 1162 | 0.040 |
Why?
|
| Bronchodilator Agents | 1 | 2021 | 506 | 0.040 |
Why?
|
| Diuresis | 1 | 2018 | 107 | 0.040 |
Why?
|
| Spain | 1 | 2019 | 487 | 0.040 |
Why?
|
| Rats, Zucker | 1 | 2017 | 132 | 0.040 |
Why?
|
| Evidence-Based Practice | 2 | 2012 | 495 | 0.040 |
Why?
|
| ROC Curve | 2 | 2010 | 3568 | 0.040 |
Why?
|
| Apoptosis | 2 | 2012 | 9497 | 0.040 |
Why?
|
| Antidotes | 1 | 2018 | 138 | 0.040 |
Why?
|
| No-Reflow Phenomenon | 1 | 2017 | 17 | 0.040 |
Why?
|
| Education | 1 | 2020 | 535 | 0.040 |
Why?
|
| Receptors, Purinergic P2Y | 1 | 2017 | 24 | 0.040 |
Why?
|
| Norepinephrine | 2 | 2014 | 900 | 0.040 |
Why?
|
| Veterans Health | 1 | 2019 | 216 | 0.040 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2019 | 239 | 0.040 |
Why?
|
| Hospices | 1 | 2021 | 256 | 0.040 |
Why?
|
| Ovariectomy | 1 | 2019 | 611 | 0.040 |
Why?
|
| Environmental Exposure | 2 | 2024 | 4404 | 0.040 |
Why?
|
| Signal Transduction | 3 | 2019 | 23363 | 0.040 |
Why?
|
| Leukocytes | 1 | 2005 | 2030 | 0.040 |
Why?
|
| Goals | 1 | 2022 | 708 | 0.040 |
Why?
|
| Stress, Mechanical | 2 | 2013 | 1666 | 0.040 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2019 | 265 | 0.040 |
Why?
|
| Body Composition | 2 | 2018 | 2418 | 0.040 |
Why?
|
| Macrophage Activation | 1 | 2020 | 553 | 0.040 |
Why?
|
| Cicatrix | 1 | 2023 | 781 | 0.040 |
Why?
|
| Procollagen | 1 | 2017 | 188 | 0.030 |
Why?
|
| Plant Proteins | 1 | 2019 | 370 | 0.030 |
Why?
|
| Physician Incentive Plans | 1 | 2018 | 165 | 0.030 |
Why?
|
| Neointima | 1 | 2017 | 134 | 0.030 |
Why?
|
| Pancreatic Neoplasms | 1 | 2014 | 5333 | 0.030 |
Why?
|
| South America | 1 | 2016 | 181 | 0.030 |
Why?
|
| Eating | 1 | 2023 | 1538 | 0.030 |
Why?
|
| Ambulances | 1 | 2016 | 92 | 0.030 |
Why?
|
| Integrins | 1 | 2001 | 840 | 0.030 |
Why?
|
| Republic of Korea | 1 | 2018 | 567 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2018 | 877 | 0.030 |
Why?
|
| Mucous Membrane | 1 | 2019 | 657 | 0.030 |
Why?
|
| Ultrasonography, Doppler | 2 | 2011 | 466 | 0.030 |
Why?
|
| Multigene Family | 1 | 2019 | 1079 | 0.030 |
Why?
|
| Stem Cell Niche | 1 | 2019 | 346 | 0.030 |
Why?
|
| Florida | 1 | 2017 | 427 | 0.030 |
Why?
|
| Limb Salvage | 1 | 2018 | 466 | 0.030 |
Why?
|
| Glyburide | 1 | 2016 | 114 | 0.030 |
Why?
|
| Organ Culture Techniques | 1 | 2017 | 796 | 0.030 |
Why?
|
| Thoracic Injuries | 1 | 2018 | 282 | 0.030 |
Why?
|
| Cineangiography | 1 | 2014 | 113 | 0.030 |
Why?
|
| Polysomnography | 1 | 2021 | 1817 | 0.030 |
Why?
|
| Organizational Objectives | 1 | 2017 | 429 | 0.030 |
Why?
|
| Partial Thromboplastin Time | 2 | 2007 | 206 | 0.030 |
Why?
|
| Patient Care Management | 1 | 2018 | 303 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2021 | 2698 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2018 | 801 | 0.030 |
Why?
|
| Safety | 1 | 2019 | 1149 | 0.030 |
Why?
|
| Access to Information | 1 | 2017 | 320 | 0.030 |
Why?
|
| Sulfonylurea Compounds | 1 | 2016 | 221 | 0.030 |
Why?
|
| Gene Frequency | 2 | 2012 | 3605 | 0.030 |
Why?
|
| Death | 1 | 2019 | 678 | 0.030 |
Why?
|
| Alzheimer Disease | 1 | 2016 | 8551 | 0.030 |
Why?
|
| Interinstitutional Relations | 1 | 2015 | 238 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2019 | 1173 | 0.030 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2019 | 788 | 0.030 |
Why?
|
| Documentation | 1 | 2020 | 892 | 0.030 |
Why?
|
| Environmental Monitoring | 1 | 2020 | 1441 | 0.030 |
Why?
|
| Efficiency, Organizational | 1 | 2019 | 697 | 0.030 |
Why?
|
| Brain Mapping | 1 | 2009 | 6562 | 0.030 |
Why?
|
| Intestinal Perforation | 1 | 2016 | 250 | 0.030 |
Why?
|
| Pregnancy | 3 | 2020 | 29725 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2021 | 2918 | 0.030 |
Why?
|
| Hormone Replacement Therapy | 1 | 2019 | 756 | 0.030 |
Why?
|
| Pressoreceptors | 1 | 2014 | 100 | 0.030 |
Why?
|
| Workflow | 1 | 2019 | 851 | 0.030 |
Why?
|
| Acylation | 1 | 2013 | 98 | 0.030 |
Why?
|
| Self Report | 2 | 2017 | 3707 | 0.030 |
Why?
|
| Platelet Membrane Glycoprotein IIb | 1 | 2013 | 52 | 0.030 |
Why?
|
| Electroencephalography | 1 | 2009 | 6182 | 0.030 |
Why?
|
| Fluid Therapy | 1 | 2017 | 593 | 0.030 |
Why?
|
| Health Care Sector | 1 | 2015 | 196 | 0.030 |
Why?
|
| International Agencies | 1 | 2014 | 244 | 0.030 |
Why?
|
| Gastrointestinal Tract | 1 | 2019 | 830 | 0.030 |
Why?
|
| Fundus Oculi | 1 | 2015 | 541 | 0.030 |
Why?
|
| Electric Impedance | 1 | 2018 | 751 | 0.030 |
Why?
|
| Serum Albumin | 1 | 2016 | 674 | 0.030 |
Why?
|
| Cognition | 2 | 2023 | 6948 | 0.030 |
Why?
|
| Directive Counseling | 1 | 2014 | 170 | 0.030 |
Why?
|
| Observer Variation | 1 | 1999 | 2596 | 0.030 |
Why?
|
| Blood Vessels | 1 | 2019 | 1112 | 0.030 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2015 | 267 | 0.030 |
Why?
|
| Infusions, Parenteral | 1 | 2013 | 404 | 0.030 |
Why?
|
| Drug Industry | 1 | 2020 | 789 | 0.030 |
Why?
|
| Venous Insufficiency | 1 | 2014 | 111 | 0.030 |
Why?
|
| Urinary Tract Infections | 1 | 2019 | 817 | 0.030 |
Why?
|
| Diet, Atherogenic | 1 | 2013 | 93 | 0.030 |
Why?
|
| Cell Differentiation | 2 | 2022 | 11480 | 0.030 |
Why?
|
| Integrin beta3 | 1 | 2013 | 121 | 0.030 |
Why?
|
| Erythrocytes | 1 | 2022 | 2415 | 0.030 |
Why?
|
| Medical Assistance | 1 | 2013 | 107 | 0.030 |
Why?
|
| Aryldialkylphosphatase | 1 | 2013 | 63 | 0.030 |
Why?
|
| Cerebral Infarction | 1 | 2018 | 982 | 0.030 |
Why?
|
| Netherlands | 1 | 2017 | 2213 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 2024 | 3145 | 0.030 |
Why?
|
| Device Approval | 1 | 2014 | 165 | 0.030 |
Why?
|
| Polypharmacy | 1 | 2015 | 307 | 0.030 |
Why?
|
| Drug Antagonism | 1 | 2012 | 51 | 0.030 |
Why?
|
| Shear Strength | 1 | 2013 | 161 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2018 | 909 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2021 | 1870 | 0.030 |
Why?
|
| Medical Staff Privileges | 1 | 2012 | 15 | 0.030 |
Why?
|
| Fluorobenzenes | 1 | 2014 | 180 | 0.030 |
Why?
|
| Foundations | 1 | 2012 | 97 | 0.030 |
Why?
|
| Arteries | 2 | 2008 | 1126 | 0.030 |
Why?
|
| Antigens, CD | 2 | 2018 | 4002 | 0.030 |
Why?
|
| Glycemic Index | 1 | 2015 | 396 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2013 | 369 | 0.030 |
Why?
|
| Electrodes | 1 | 2014 | 614 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 2018 | 1840 | 0.030 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2013 | 273 | 0.030 |
Why?
|
| Intestinal Obstruction | 1 | 2016 | 435 | 0.030 |
Why?
|
| Discriminant Analysis | 1 | 2012 | 223 | 0.030 |
Why?
|
| Frail Elderly | 1 | 2017 | 747 | 0.020 |
Why?
|
| Temperature | 1 | 2018 | 2221 | 0.020 |
Why?
|
| Tubulin Modulators | 1 | 2012 | 107 | 0.020 |
Why?
|
| Knowledge Bases | 1 | 2012 | 98 | 0.020 |
Why?
|
| Oxygen | 2 | 2014 | 4189 | 0.020 |
Why?
|
| Postprandial Period | 1 | 2013 | 315 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2018 | 1137 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 2024 | 2532 | 0.020 |
Why?
|
| General Practitioners | 1 | 2013 | 102 | 0.020 |
Why?
|
| Menopause | 1 | 2019 | 1640 | 0.020 |
Why?
|
| Phylogeny | 1 | 2019 | 2775 | 0.020 |
Why?
|
| Models, Anatomic | 1 | 2015 | 682 | 0.020 |
Why?
|
| Oximetry | 1 | 2014 | 461 | 0.020 |
Why?
|
| Hypogonadism | 1 | 2018 | 800 | 0.020 |
Why?
|
| Immunologic Memory | 1 | 2018 | 1354 | 0.020 |
Why?
|
| Differential Thermal Analysis | 1 | 2011 | 1 | 0.020 |
Why?
|
| Denmark | 1 | 2014 | 759 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2019 | 2777 | 0.020 |
Why?
|
| Apoenzymes | 1 | 2011 | 18 | 0.020 |
Why?
|
| Apolipoprotein E4 | 1 | 2016 | 708 | 0.020 |
Why?
|
| Holoenzymes | 1 | 2011 | 40 | 0.020 |
Why?
|
| Indiana | 1 | 2011 | 93 | 0.020 |
Why?
|
| Information Storage and Retrieval | 1 | 2016 | 821 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2018 | 1826 | 0.020 |
Why?
|
| Interleukin-11 | 1 | 2010 | 59 | 0.020 |
Why?
|
| Membranes, Artificial | 1 | 2012 | 367 | 0.020 |
Why?
|
| General Practice | 1 | 2012 | 98 | 0.020 |
Why?
|
| Carotid Artery Thrombosis | 1 | 2010 | 51 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 2014 | 1098 | 0.020 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2011 | 169 | 0.020 |
Why?
|
| Polyesters | 1 | 2012 | 372 | 0.020 |
Why?
|
| Rabbits | 1 | 2017 | 4773 | 0.020 |
Why?
|
| Macrophages | 1 | 2005 | 5745 | 0.020 |
Why?
|
| Conflict of Interest | 1 | 2015 | 549 | 0.020 |
Why?
|
| Smad3 Protein | 1 | 2010 | 168 | 0.020 |
Why?
|
| Peer Review | 1 | 2012 | 218 | 0.020 |
Why?
|
| Regeneration | 1 | 2019 | 1506 | 0.020 |
Why?
|
| Cerebrovascular Circulation | 1 | 2020 | 2731 | 0.020 |
Why?
|
| Skin Pigmentation | 1 | 2012 | 277 | 0.020 |
Why?
|
| Time | 1 | 2012 | 545 | 0.020 |
Why?
|
| Nomograms | 1 | 2012 | 238 | 0.020 |
Why?
|
| Tissue Scaffolds | 1 | 2017 | 927 | 0.020 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2019 | 907 | 0.020 |
Why?
|
| Pressure | 1 | 2013 | 1155 | 0.020 |
Why?
|
| Statistics as Topic | 2 | 2009 | 2363 | 0.020 |
Why?
|
| Cycloleucine | 1 | 2009 | 8 | 0.020 |
Why?
|
| Loneliness | 1 | 2012 | 196 | 0.020 |
Why?
|
| Singapore | 1 | 2010 | 287 | 0.020 |
Why?
|
| Private Sector | 1 | 2013 | 398 | 0.020 |
Why?
|
| alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 1 | 2009 | 70 | 0.020 |
Why?
|
| Phenotype | 2 | 2020 | 16543 | 0.020 |
Why?
|
| Leptin | 1 | 2018 | 1590 | 0.020 |
Why?
|
| Saskatchewan | 1 | 2009 | 9 | 0.020 |
Why?
|
| Isoenzymes | 2 | 2005 | 1690 | 0.020 |
Why?
|
| Receptors, Kainic Acid | 1 | 2009 | 90 | 0.020 |
Why?
|
| Taiwan | 1 | 2010 | 503 | 0.020 |
Why?
|
| Proteomics | 1 | 2023 | 3810 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2018 | 4814 | 0.020 |
Why?
|
| Kainic Acid | 1 | 2009 | 199 | 0.020 |
Why?
|
| Israel | 1 | 2011 | 722 | 0.020 |
Why?
|
| Surgical Wound Infection | 1 | 2018 | 1529 | 0.020 |
Why?
|
| Cultural Characteristics | 1 | 2010 | 253 | 0.020 |
Why?
|
| Suburban Population | 1 | 2009 | 54 | 0.020 |
Why?
|
| Serine Endopeptidases | 1 | 2014 | 1021 | 0.020 |
Why?
|
| Anemia, Macrocytic | 1 | 2009 | 54 | 0.020 |
Why?
|
| Rats, Inbred Strains | 1 | 1990 | 2094 | 0.020 |
Why?
|
| Thiazoles | 1 | 2016 | 1509 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2019 | 2918 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2020 | 8157 | 0.020 |
Why?
|
| Disulfides | 1 | 2011 | 466 | 0.020 |
Why?
|
| Antidepressive Agents | 1 | 2021 | 2889 | 0.020 |
Why?
|
| Consumer Product Safety | 1 | 2009 | 123 | 0.020 |
Why?
|
| Afferent Pathways | 1 | 2009 | 299 | 0.020 |
Why?
|
| Prescription Drugs | 1 | 2015 | 630 | 0.020 |
Why?
|
| Erythrocyte Indices | 1 | 2009 | 145 | 0.020 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1990 | 941 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2011 | 1158 | 0.020 |
Why?
|
| Glutamates | 1 | 2009 | 391 | 0.020 |
Why?
|
| HIV-1 | 1 | 2005 | 6850 | 0.020 |
Why?
|
| Infrared Rays | 1 | 2009 | 246 | 0.020 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2009 | 369 | 0.020 |
Why?
|
| Receptors, AMPA | 1 | 2009 | 323 | 0.020 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2019 | 3601 | 0.020 |
Why?
|
| Larva | 1 | 2009 | 509 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2024 | 5640 | 0.020 |
Why?
|
| Ankle | 1 | 2011 | 350 | 0.020 |
Why?
|
| Cell Size | 1 | 2009 | 623 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2013 | 1731 | 0.020 |
Why?
|
| Learning | 1 | 2017 | 1733 | 0.020 |
Why?
|
| Lactic Acid | 1 | 2012 | 1132 | 0.020 |
Why?
|
| Observation | 1 | 2009 | 312 | 0.020 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2007 | 114 | 0.020 |
Why?
|
| Lupus Coagulation Inhibitor | 1 | 2007 | 34 | 0.020 |
Why?
|
| Cerebral Arteries | 1 | 2009 | 493 | 0.020 |
Why?
|
| Hemoglobins | 2 | 2004 | 1521 | 0.020 |
Why?
|
| Physician's Role | 1 | 2014 | 920 | 0.020 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2008 | 137 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 2753 | 0.020 |
Why?
|
| Geriatric Assessment | 1 | 2014 | 1405 | 0.020 |
Why?
|
| Equipment Failure Analysis | 1 | 2009 | 848 | 0.020 |
Why?
|
| Prothrombin | 1 | 2007 | 191 | 0.020 |
Why?
|
| Drug Hypersensitivity | 1 | 2015 | 912 | 0.020 |
Why?
|
| Pneumonia | 1 | 2018 | 2138 | 0.020 |
Why?
|
| Curriculum | 1 | 2019 | 3722 | 0.020 |
Why?
|
| Long QT Syndrome | 1 | 2010 | 465 | 0.020 |
Why?
|
| Health Services Research | 1 | 2013 | 1811 | 0.020 |
Why?
|
| Hip Fractures | 1 | 2014 | 989 | 0.020 |
Why?
|
| Quantitative Trait Loci | 1 | 2014 | 2101 | 0.020 |
Why?
|
| Visual Acuity | 1 | 2015 | 2635 | 0.020 |
Why?
|
| Pravastatin | 1 | 2007 | 393 | 0.020 |
Why?
|
| Mutation | 2 | 2010 | 29950 | 0.020 |
Why?
|
| Monitoring, Ambulatory | 1 | 2008 | 353 | 0.020 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2007 | 412 | 0.020 |
Why?
|
| Intramolecular Transferases | 1 | 2004 | 15 | 0.020 |
Why?
|
| Anthropometry | 1 | 2009 | 1348 | 0.020 |
Why?
|
| Alleles | 1 | 2016 | 6900 | 0.010 |
Why?
|
| Amino Acids | 1 | 2011 | 1715 | 0.010 |
Why?
|
| Medical History Taking | 1 | 2008 | 773 | 0.010 |
Why?
|
| Diet, Reducing | 1 | 2008 | 487 | 0.010 |
Why?
|
| Gene Expression | 1 | 2017 | 7592 | 0.010 |
Why?
|
| Platelet Membrane Glycoproteins | 1 | 2005 | 285 | 0.010 |
Why?
|
| Ireland | 1 | 2004 | 172 | 0.010 |
Why?
|
| Middle Cerebral Artery | 1 | 2005 | 275 | 0.010 |
Why?
|
| International Cooperation | 1 | 2010 | 1436 | 0.010 |
Why?
|
| Atropine | 1 | 2004 | 245 | 0.010 |
Why?
|
| Louisiana | 1 | 2003 | 104 | 0.010 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2004 | 178 | 0.010 |
Why?
|
| Benzodiazepines | 1 | 2009 | 1132 | 0.010 |
Why?
|
| Causality | 1 | 2009 | 1241 | 0.010 |
Why?
|
| Synaptic Transmission | 1 | 2009 | 1169 | 0.010 |
Why?
|
| Economics, Pharmaceutical | 1 | 2003 | 88 | 0.010 |
Why?
|
| Protein Precursors | 1 | 2007 | 1135 | 0.010 |
Why?
|
| Factor Xa | 1 | 2004 | 168 | 0.010 |
Why?
|
| Depression | 2 | 2016 | 8033 | 0.010 |
Why?
|
| Employment | 1 | 2009 | 1111 | 0.010 |
Why?
|
| Pennsylvania | 1 | 2003 | 615 | 0.010 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2001 | 49 | 0.010 |
Why?
|
| Computational Biology | 1 | 2014 | 3504 | 0.010 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2005 | 825 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 7400 | 0.010 |
Why?
|
| Species Specificity | 1 | 2005 | 2413 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2005 | 2178 | 0.010 |
Why?
|
| Bleeding Time | 1 | 2000 | 84 | 0.010 |
Why?
|
| Anxiety | 1 | 2016 | 4532 | 0.010 |
Why?
|
| Pain | 1 | 2016 | 5066 | 0.010 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2001 | 326 | 0.010 |
Why?
|
| Infant | 1 | 2022 | 36030 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 2016 | 4440 | 0.010 |
Why?
|
| Pharmaceutical Preparations | 1 | 2008 | 1093 | 0.010 |
Why?
|
| Asthma | 1 | 2019 | 6167 | 0.010 |
Why?
|
| Suicide | 1 | 2010 | 1599 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2022 | 42034 | 0.010 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2003 | 450 | 0.010 |
Why?
|
| Hematoma | 1 | 2003 | 769 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2005 | 1828 | 0.010 |
Why?
|
| Protein Binding | 1 | 2011 | 9336 | 0.010 |
Why?
|
| Escherichia coli | 1 | 2011 | 4223 | 0.010 |
Why?
|
| Health Surveys | 1 | 2008 | 4061 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 1999 | 749 | 0.010 |
Why?
|
| Virus Replication | 1 | 2005 | 2431 | 0.010 |
Why?
|
| Mice | 1 | 2024 | 81216 | 0.010 |
Why?
|
| Endothelial Growth Factors | 1 | 1999 | 674 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 3804 | 0.010 |
Why?
|
| Lymphokines | 1 | 1999 | 929 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2002 | 2852 | 0.010 |
Why?
|
| Headache | 1 | 2004 | 1249 | 0.010 |
Why?
|
| Demography | 1 | 2001 | 1650 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2005 | 13456 | 0.010 |
Why?
|
| Primary Health Care | 1 | 2010 | 4649 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2005 | 17628 | 0.010 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2001 | 2047 | 0.010 |
Why?
|
| Mental Disorders | 1 | 2010 | 6797 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 1999 | 3483 | 0.000 |
Why?
|